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1 Introduction 
1.1 Schizophyllan 
Schizophyllan (SCH) is a neutral and water soluble homopol-
ysaccharide, that consists of a β-(1,3)-D-glucan main chain 
with additional single β-(1,6)-bound D-glucose at every third 
glucose moiety of the backbone [1]. Reports of the average 
molecular weight range from 5.7 x 106  to 1.3 x 107 g mol-1 
[2, 3]. It is produced as extracellular polysaccharide by the 
wood rotting basidiomycete Schizophyllum commune also 
commonly known as Split Gill [4]. 
 
 
Figure 1-1 Smallest repeating unit (RU) of Schizophyllan, 
three β-(1,3)-linked D-glucose with a single β-(1,6)-bound D-
glucose as branch with n = 8,810 to 20,093. 
 
In aqueous solution SCH forms a triple helical structure com-
posed of three twisted SCH chains with the β-(1,6)-bound 
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glucose residues directed to the outside [3, 5–7]. The height 
of one helix turn and the average helix diameter were deter-
mined as 1.8 nm and 2.6 nm, respectively [6, 7]. The triplex 
is understood to be stabilized by hydrogen bonds, especially 
between the C-2 hydroxyl groups of the glucose molecules 
at the glucan backbones [8]. Due to the high stability of the 
triplex, dissociation into single strands occurs only at tem-
peratures above 135 °C, at pH above 12 or by supplementa-
tion with at least 87 % (w/w) or higher of dimethyl sulfoxide 
[3, 7, 9]. The denaturation of the structure is particular pos-
sible and recovery of initial conditions leads to formation of 
random coiled structures [3, 7, 9, 10]. 
Solutions of triple helical SCH show high viscosity with pseu-
doplastic flow behavior [4, 11]. The triplex conformation is 
considered to be primarily responsible for this property 
since the breakup into single strands leads to strong reduc-
tion of viscosity [3, 7, 9]. Because of the stability of the vis-
cosity at high temperatures and high salt concentrations, 
SCH is tested as agent for polymer flooding in enhanced oil 
recovery [12, 13]. Due to its biophysical properties, the glu-
can has further potential applications e.g. as component of 
lubricants, thickening agent and moisturizing cosmetic. 
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Figure 1-2 Model of the Schizophyllan triple helix structure 
(SCH chain 1 in red; SCH chain 2 in black; SCH chain 3 in grey). 
One helix turn with 1.8 nm height consists of six β-(1,3)-linked 
main chain D-glucose monomers and an average helix diame-
ter of 2.6 nm with the protruding β-(1,6)-bound D-glucose 
(modeled by Dr. Kwang Hoon Sung, Helmholtz Centre for In-
fection research, Braunschweig, Germany). 
 
Like a variety of other fungal β-(1,3)-D-glucans, SCH shows 
antitumoral and immunomodulating effects [14]. It is re-
ported to be effective in mice against solid forms of sarcoma 
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37, sarcoma 180, Ehrlich carcinoma and Yoshida sarcoma, as 
well as 7,12-dieŵthǇlďeŶz;αͿaŶthraĐeŶe induced hepatic 
and mammary carcinoma [15, 16]. From clinical trials of ra-
diation and chemotherapy with SCH as assistant agent, a 
prolonged survival time of patients could be observed ex-
plained by aiding against radiation damage and accelerated 
recovery of bone marrow function [17–19]. Results of stud-
ies in vivo in mice and in vitro suggest that its bioactivity is 
based on the enhancement of cell-mediated immune re-
sponse with stimulation of T-lymphocytes as well as macro-
phages and improving cytokine production [20–25]. 
1.2 Theoretical basics on antibody generation 
1.2.1 Antibodies 
Antibodies are proteins of the immunoglobulin (Ig) family 
and an essential part of the humoral adaptive immune sys-
tem in Gnathostomes (higher vertebrates with jaws). They 
are produced and secreted by B-lymphocytes as conse-
quence of an immune response [26]. The primary function 
of antibodies is the specific binding to pathogens and their 
toxic products as well as other extracellular immunogenic 
particles. By binding they induce three protective mecha-
nisms: Neutralization through blocking of the interaction 
with cells, opsonization to prompt recognition by 
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phagocytes for elimination and activation of the comple-
mentary system that eliminates directly and improves recog-
nition by phagocytes [27]. The recognition of antibodies as 
therapeutic agent in medicine and as analytic tool in diag-
nostic and research, drove to the development of a research 
area specialized on the generation of antibodies. 
The general antibody structure consists of four polypeptide 
chains connected by disulfide-bonds and non-covalent inter-
actions. One pair of identical chains with a size of ≈50 kDa or 
higher (heavy chain, HC) is bound to each other in their C-
terminal region. While two identical chains of ≈25 kDa (light 
chain, LC) are attached to the N-terminal region of the heavy 
chains. This results in a Y-shaped molecule, with two N-ter-
minal regions involved in antigen binding (Fab, fragment an-
tigen binding) and one C-terminal region responsible for the 
effector mechanism (Fc, fragment crystallizable). Different 
structural und functional properties of the heavy chain di-
vide antibodies into different classes (isotypes) for example, 
in human exist 5 classes: IgA (IgA1 & IgA2), IgD, IgE, IgG 
(IgG1-IgG4) and IgM [27–29]. Antibodies of the IgG class are 
the most abundant isotypes of human blood and are further 
described in the following paragraph.  
 
 
Introduction 
6 
 
Figure 1-3 Schematic structure of an immunoglobulin G, IgG. 
Antibodies are composed of two identical heavy protein 
chains (HC) and two identical light chains (LC). The HC of the 
IgG isotype consists of three IgG specific constant domains 
(CH1, CH2 & CH3) and one variable domain (VH). Both HCs are 
connected by disulfide bonds at their hinge region. The LC con-
sists of two domains, one constant domain (CL) and one varia-
ble domain (VH). Each LC is bound to one of the heavy chains 
by a disulfide bond between CH1 and CL domains. The resulting 
Y-shaped molecule can be subdivided into three fragments, 
two identical fragments needed for antigen binding (fragment 
antigen binding, Fab) and one fragment responsible for the ef-
fector activity (fragment crystallizable, Fc). The Fc is formed by 
the N-glycosylated CH2 and the CH3 domains of both HCs. 
While each Fab is formed by CH1 and VH of one HC as well as 
the respective LC. VH and VL in a Fab represent the smallest 
functional antigen binding unit called Fv (fragment variable). 
Both domains contain three hyper variable sequence regions 
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(complementarity determining regions, CDRs) which are the 
components of the antibody paratope and determine its anti-
gen complementarity. 
 
The IgG heavy chain has a size of ≈50 kDa and possess four 
structural domains (β-barrels) VH, CH1, CH2, CH3, a flexible 
peptide linker (hinge region) between CH1 and CH2 as well as 
a N-glycosylation in CH2. The N-terminal VH is a domain with 
variable sequence while CH1 to CH3 are domains with a con-
stant sequence specific for the Ig class. As for every Ig iso-
type, the light chain is either of the kappa or the lambda 
type, depending from which of the two chromosomal LC 
gene loci they originated. They have two structural domains: 
the variable domain VL and the constant domain CL. Disulfide 
bonds between the CH1 and CL domain and between the 
hinge regions of the heavy chains connect the polypeptides. 
Together the N-terminal domains VH and VL form the small-
est unit of the antibody that leads to antigen binding, the Fv 
(Fragment variable). Each of the variable domains has three 
hypervariable sequence regions, which are located in the 
loop-structures of the beta barrels. They form the region of 
the domains that non-covalently interacts with the antigen, 
the paratope. Since their sequence determines the specific-
ity for an antigen epitope, they are also called CDRs 
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(complementary determining regions). The residual parts of 
the V-domains are the framework regions which are in-
volved in stabilization of the paratope structure [27–29]. 
Some applications for antibodies are based only on antigen 
binding and do not depend on the effector mechanism or 
even need novel Ig-unlike properties. Therefore, different 
recombinant antibody formats have been developed and 
studied. Here, the formats used in this work are described: 
Single chain Fv (scFv), single chain Fv fused to Fc (scFv-Fc) 
and Fab.  
The scFv format is an analog to the Fv region of antibodies 
with a size of 25 - 30 kDa. It consists of a VL and VH domain 
connected to each other by a peptide linker, which promotes 
the formation and stabilization of the paratope [30, 31]. In 
the scFv-Fc format, a scFv is fused to the CH2 and CH3 do-
mains via the hinge region. Through the connections of the 
hinge regions of two scFv-Fc chains, it forms an IgG-like 
structure of approx. 110 kDa size with scFvs instead of Fabs 
and shows IgG-like functional effects [32]. The Fab format 
(approx. 50 kDa) equals the Fab part of immunoglobulins 
and can be derived recombinant but also non-recombinant 
by treatment of IgG with the protease pepsin [28]. 
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Figure 1-4 Schematic structures of the antibody format scFv, 
scFv-Fc and Fab. The recombinant antibody format scFv (sin-
gle chain Fv, on the left) is derived from connecting the VH and 
VL with a short linker peptide. Another recombinant format is 
the scFv-Fc (in the middle) with a scFv connected to the IgG 
domains CH2 and CH3 via the hinge region. Through the inter-
chain disulfide bonds of the hinge region it mimics an IgG with 
its two antigen binding sites and a functional Fc. The Fab of an 
IgG (right) can be produced as recombinant molecule or by 
pepsin treatment of an IgG. 
 
1.2.2 Antibody generation 
The first developed method for antibody generation is the 
isolation of sera from animals which were immunized with 
the antigen of interest. The purified anti sera hold an en-
riched mixture of different antibodies (polyclonal antibod-
ies) against the pathogen. Later in 1975 Köhler and Milstein 
developed a technology for fusing B-lymphocytes from the 
spleen of an immunized mice with myeloma cells, the 
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hybridoma technology [33]. The resulting hybridoma cells 
obtain the properties of both cells: antigen specificity, anti-
body secretion and immortality. This technology enabled the 
selection of one specific antibody (monoclonal antibody) 
with desired antigen binding properties and the unlimited 
availability for production of this antibody. 
Today - in consequence of the ongoing development of the 
recombinant DNA technology - it is also possible to generate 
monoclonal antibodies in vitro directly from a library of an-
tibody genes and to produce them in different expression 
systems. Antibody gene libraries are derived from humans 
or other Gnathostomes by isolating the antibody genes from 
a repertoire of B-lymphocytes in a defined sample [34]. An 
immune antibody gene library is constructed by isolation of 
the antibody genes from IgG secreting B-lymphocytes after 
immunization [35]. Due to the immunization with the anti-
gen of interest, the library contains maturated antibodies 
with high affinity for the antigen. Whereas an universal anti-
body gene library is generated by isolation of antibody genes 
from IgM presenting B-lymphocytes and presents a reper-
toire of naive antibodies against a high number of antigens 
[36]. The high diversity allows the isolation of antibodies 
against different antigens from one library but the antibod-
ies show lower affinities. The diversity of universal libraries 
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can be further increased by additional randomization of the 
CDR3 regions (semi-synthetic gene library) or of all CDR re-
gions in the variable domains (synthetic gene library) [37, 
38]. 
Selection of the desired antibody from those libraries is pos-
sible by using display technologies. All display technologies 
have in common that a protein or peptide is expressed and 
physically coupled to its genetic information. This allows the 
selection of desired antibodies for their specificity and the 
direct isolation of their genetic information. Examples are 
the ribosome display with covalent fixation of the mRNA-ri-
bosome-protein complex, the phage display with packaging 
of the gene into phage particles presenting its product fused 
to a phage coat protein and the yeast display with transfor-
mation of a gene into yeast cells and its expression as cell 
surface protein fusion [39–41]. The antibody phage display 
with the bacteriophage M13 used in this work is further de-
scribed in the next chapter. 
1.2.3 Antibody phage display 
The E. coli specific bacteriophage M13 is a filamentous 
phage (length 930 nm & diameter 6.5 nm) with a circular and 
single stranded DNA genome (6.5 kb). Its genome consists of 
the M13 origin and eleven additional genes: g2, g5 and g10 
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are coding proteins responsible for replication of the phage 
DNA; g1, g4 and g11 are coding proteins responsible for the 
assembly of the phage particles; g3, g6, g7, g8 and g9 coding 
for the phage coat proteins. The product of g8 is the main 
coat protein p8 with some thousand copies ;≈2700) per 
phage. Five copies of the other coat proteins are assembled 
on the tail end (p7 & p9) and on the head end (p3 & p6).  
 
 
Figure 1-5 Schematic of bacteriophage M13 and its genome. 
The circular ssDNA (single stranded DNA) genome of bacterio-
phage M13 is packed in a filamentous particle that consists 
mainly of the coat protein p8 ;≈ϮϳϬϬ ĐopiesͿ. At the head end 
of the particle are five copies of the coat proteins p6 and p3 
and at the tail end five copies of p7 and p9. Next to the genes 
for the coat proteins (g3, g6, g7, g8 & g9) the genome contains 
genes for genome replication in E. coli (g2, g5 & g10) and for 
the assembly new phage particles at the cell membrane (g1, 
g4 & g11) as well as the M13ori sequence. 
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Infection of E. coli is induced by binding of p3 to the F-pili 
and to the surface protein TolA. The phage replication does 
not kill the cells but leads to a reduced growth rate. New 
phage particles emerge from the cell by adding of the inner 
membrane located coat proteins to the genome while it is 
passing through the periplasm to the outside [42].The most 
commonly used method for antibody phage display is the fu-
sion of the antibodies in the scFv format to the coat protein 
p3. Variants with the fusion to the other coat proteins and 
with the usage of different antibody formats are also tested 
and described [43–46]. For construction of phage displayed 
antibody libraries special vectors were developed that can 
be packed into phage particles. They consist of an expression 
cassette for the scFv-p3 fusion protein, an antibiotic re-
sistance gene, an E. coli origin of replication for non-phage 
mediated replication and a M13 origin of replication for 
packaging into phage particles. The expression cassette con-
tains a LacZ promotor, the pelB leader for translocation of 
the scFv into the periplasm, cloning sites for the integration 
of the V domain genes, a linker sequence with myc-tag and 
amber stop codon as well as the g3 sequence [47, 48]. 
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Figure 1-6 Schematic of a bacteriophage M13 based antibody 
phage particle and the respective phagemid. The antibody 
phage (left) contains a phagemid packed with the coat pro-
teins of the bacteriophage M13. Depending on the helper 
phage used for packaging, the antibody phage presents on its 
surface one to five copies of a scFv as scFv-p3 fusion protein. 
The phagemid consists of an expression cassette coding for the 
scFv-p3 fusion protein, the bacterial origin of replication Col E1 
(Col E1 ori) for phagemid amplification, the origin of replica-
tion from bacteriophage M13 as phage packaging signal and 
the β-lactamase gene as antibiotic resistance for selection. The 
expression cassette is framed by an inducible lac promotor 
and a terminator sequence for transcription. It also possesses 
the ribosome binding site sequence (RBS) for the translation 
of the scFv-p3 fusion protein. The sequence for the expressed 
fusion protein contains the pelB leader for translocation of the 
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scFv into the periplasm, the scFv (VH, Linker & VL) and the fused 
p3 (Linker & g3). For cloning, the VH and VL sequences are 
framed by the recognition sites of the endonucleases NcoI, 
HindIII, MluI and NotI. Furthermore, the linker sequence be-
tween scFv and g3 includes the sequence for a myc-tag and 
contains an amber stop codon. 
 
After transformation of the phage display vector into the 
host, an infection with helper phage is necessary to produce 
the antibody displaying phage particles. The helper phage 
delivers the genetic information to produce the phage pro-
teins needed for phage formation. It is repressed in its own 
replication and depending on the helper phage strain leads 
to different amount of presented scFv-p3 fusion proteins on 
the phage particle. Helper phage M13K07 results in antibody 
phage particles with an average of one presented scFv-p3 fu-
sion protein per 10 particles [49, 50]. Infection with the 
strain hyperphage results in the maximal presentation of five 
scFv-p3 fusion proteins per particle [51]. 
Isolation of the desired antibodies from a phage displayed 
antibody library is conducted by two or three rounds of se-
lection and amplification, also called panning [52, 53]. The 
phage displayed antibody library is incubated with an immo-
bilized antigen of interest, through extensive washing the 
non-binding and weak binding antibody phage are removed. 
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Figure 1-7 Schematic of the procedure for the selection of 
monoclonal antibodies from an antibody phage library via 
panning. The antibody phage library is incubated with the im-
mobilized antigen. Weak and not bound antibody phage are 
washed away. The bound antibody phage are eluted with tryp-
sin or via pH-shift and used for the infection of E. coli cells. In-
fected cells are co infected with helper phage for production 
of new antibody phage. The derived antibody phage prepara-
tion enriched by antigen binding antibody phage is used for 
another round of selection. After 2 to 3 rounds of selection, 
single clones of the infected E. coli are isolated and used for 
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production of the monoclonal antibodies. Produced and anti-
gen-specific antibodies are identified via immunoassay. 
 
The bound phage are eluted from the immobilized antigen 
by trypsin treatment or pH shift and used for infection of 
E. coli cells [54]. After production of new antibody phage 
particles, the enriched library is used for one or two further 
rounds of selection. Single clones of the E. coli cells infected 
with the selected phages from the last round are isolated. 
Through the weak amber stop codon and induction by IPTG, 
the isolated clones are able to produce the scFvs as solved 
proteins in a sufficient amount for detection [55]. The cul-
ture supernatants of the clones are screened by antigen 
ELISA for specific scFvs. Now, the scFv sequence of a positive 
tested clone can be isolated and used for further character-
ization of the selected monoclonal antibody. 
1.3 Objective of this study 
Due to the various properties of SCH which make it interest-
ing for different applications, anti-SCH antibodies would be 
of great value as tool for quantitative analysis and for the 
investigation of glucan bioactivity. The objective of this study 
was the generation of such recombinant monoclonal anti-
bodies against the β-D-glucan Schizophyllan from an 
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immune library as well as from a naive library. Isolation of 
the respective antibodies should be performed via phage 
display. Therefore, a suitable immobilization method of SCH 
to a solid carrier matrix had to be established. At last the an-
tigen specificity of the isolated antibodies should be charac-
terized. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
The equipment used in this project is listed in the following 
table: 
 
Table 2-1 List of equipment used in this project 
Device Model Manufacturer 
Balances Sartorius  
analytic 
Sartorius, Göttingen,  
Germany 
 Sartorius  
excellence 
Sartorius, Göttingen,  
Germany 
Blotting machine Trans-Plot® Turbo™ Bio-Rad Laboratories, 
München, Germany 
Centrifuges 5810 R Eppendorf, Hamburg,  
Germany 
 5415 D Eppendorf, Hamburg,  
Germany 
 Multifuge® 3 S-R Heraeus, Hanau,  
Germany 
 Multifuge® 1 S-R Thermo Scientific,  
Dreieich, Germany 
 Sorǀall™ RCϲ Plus Thermo Scientific,  
Dreieich, Germany 
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 Sprout® Heathrow Scientific, 
Illinois, USA 
Chromatography 
system 
ÄKTApurifier™ GE Healthcare,  
München, Germany 
Desiccator SICCO Star-Vitrum Bohlender, Grünsfeld,  
Germany 
Electrophoresis 
chamber 
Mini-Protean® 3  Bio-Rad Laboratories,  
München, Germany 
 Model 40-0708/ 
40-1410 
Peqlab, Erlangen,  
Germany 
Electroporation  
device 
MiĐroPulser™ Bio-Rad Laboratories,  
München, Germany 
ELISA readers EpoĐh™ BioTek Instruments,  
Winooski, USA 
 SuŶrise™ Tecan, Crailsheim,  
Germany 
ELISA washer HǇdroFleǆ™ Tecan, Crailsheim,  
Germany 
Gel documenta-
tion system 
Gel Jet Imager Intas, Göttingen, 
Germany 
Incubators Certomat® BS-1 Braun, Melsungen, 
Germany 
 HERAĐell™ Thermo Scientific,  
Dreieich, Germany 
 Minitron Infors HT, Bottmingen, 
Switzerland 
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 Multitron Infors HT, Bottmingen, 
Switzerland 
 Typ BE400 Memmert, Schwabach, 
Germany 
 VorTeŵp™ ϱϲ Labnet, Woodbridge, 
USA 
Laminar flow 
benches 
Hera safe™ Heraeus, Hanau, 
Germany 
 HLB 2472 Heraeus, Hanau, 
Germany 
 MSC-AdǀaŶtage™ Thermo Scientific, 
Dreieich, Germany 
Liquid handling  
system 
EL406 BioTek Instruments, 
Winooski, USA 
Multiwell plate 
stackers 
BiostaĐk™ ϯ BioTek Instruments, 
Winooski, USA 
 BiostaĐk™ ϰ BioTek Instruments, 
Winooski, USA 
Orbital shakers Celltron Infors HT, Bottmingen, 
Switzerland 
 Titramax 101 Heidolph, Schwabach, 
Germany 
Oven Heratherm® Thermo Scientific, 
Dreieich, Germany 
pH meter CG810 Schott, Mainz, 
Germany 
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Photometers NaŶoDrop™  
ND1000 
Peqlab, Erlangen,  
Germany 
 Libra S11 Biochrom, Holliston, 
USA 
Pipettes e1200 BIOHIT, Helsinki,  
Finland 
 Multipette® Plus Eppendorf, Hamburg,  
Germany 
 Eppendorf Research® Eppendorf, Hamburg, 
Germany 
 VIAFLO 96 INTEGRA Biosciences, 
Zizers, Switzerland 
Power supply EPS 301 Amersham Bioscience, 
Freiburg, Germany 
Protein purifica-
tion system 
ProfiŶia™ Bio-Rad Laboratories, 
München, Germany 
Peristaltic pump MasterFleǆ® L/S™ Cole-Palmer, 
Wertheim, 
Germany 
Rotors A-4-81 Eppendorf, Hamburg, 
Germany 
 BIOShield™ ϭϬϬϬA Heraeus, Hanau, 
Germany 
 F12S-6x500y FIBERLite, Santa Clara, 
USA 
 HIGHCoŶiĐ™ Thermo Scientific, 
Dreieich, Germany 
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 Microlitre rotor AL Heraeus, Hanau,  
Germany 
 SS-34 (Sorvall) Thermo Scientific,  
Dreieich, Germany 
Sterilizer FVA/A1 Fedegari Autoclavi, 
Albuzzano, Italy 
Thermocycler PTC-200  
DNA Engine® 
MJ Research, Waltham, 
USA 
Thermomixers Thermomixer®  
Comfort 
Eppendorf, Hamburg, 
Germany 
 Thermomixer®  
Compact 
Eppendorf, Hamburg, 
Germany 
Vacuum oven VaĐutherŵ™ Thermo Scientific,  
Dreieich, Germany 
Vacuum manifold NucleoVac 96 Macherey-Nagel,  
Düren, Germany 
Vacuum pumps MZ 2C NT VACUUBRAND,  
Wertheim, Germany 
 N 035.1.2 AT.18 KNF Neuberger, 
Freiburg, Germany 
Water baths 1002/1003 GFL, Burgwedel, 
Germany 
 SW20 Julapo, Seelbach, 
Germany 
Water installation Arium® 611 Sartorius, Göttingen, 
Germany 
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2.1.2 Consumables 
The consumables used in this project are listed in the follow-
ing table: 
 
Table 2-2 List of consumables used in this project 
Material Manufacturer 
  
AeraSeal™, multiwell plate cover seal Excel Scientific, 
Victorville, USA 
Air-o-Seal – hydrophobic gas  
permeable seal 
4titude, Dorking, UK 
Amicon® Ultra – 0.5 mL Centrifugal  
Filters, 30 kDa cut-off 
Merck Millipore, 
Darmstadt, Germany 
CentriStar™, Centrifugation tubes Corning, New York,  
USA 
Chelating Sepharose® Fast Flow GE Healthcare, München, 
Germany 
Combitips™ plus Eppendorf, Hamburg, 
Germany 
Costar® disposable serelogical  
pipettes 
Corning, New York, USA 
Costar® Carbo-BIND™ 
96-well multiwell plate 
Corning, New York, USA 
Deep well plates Thermo Scientific, 
Dreieich, Germany 
Disposable cuvettes Brand, Wertheim, 
Germany 
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DǇŶaďeads™ M-270 Amine Thermo Scientific, 
Dreieich, Germany 
DǇŶaďeads™ M-270 Epoxy Thermo Scientific, 
Dreieich, Germany 
Electroporation cuvettes, 
Gene Pulser® 0.1 cm 
Bio-Rad Laboratories, 
München, Germany 
Inoculation loops VWR, Darmstadt, 
Germany 
MaďSeleĐt™ SuRe™ 
(protein A resin) 
GE Healthcare, München, 
Germany 
Multiwell plate seal 4titude, Dorking, UK 
Multiply®-µStrip Pro 8-strip Sarstedt, Nümbrecht, 
Germany 
Petri dishes Greiner Bio-One, 
Frickenhausen, Germany 
Pipette tips Sarstedt, Nümbrecht, 
Germany 
Pipette tips INTEGRA Biosciences, 
Zizers, Switzerland 
Pipette tips, filtered Greiner-Bio-One, 
Frickenhausen, Germany 
Pipette tips, filtered Nerbe plus, Winsen, 
Germany 
Polycarbonate Erlenmeyer flask with 
vent cap 
Corning, New York, USA 
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Polypropylene 96-Well multiwell plate, 
Flat-shaped 
Greiner-Bio-One, 
Frickenhausen, Germany 
Polypropylene 96-Well multiwell plate, 
U-shaped 
Greiner-Bio-One, 
Frickenhausen, Germany 
Polypropylene screw cap tube, 
40 mL 
Sarstedt, Nümbrecht, 
Germany 
Polystyrene lid for multiwell plate Greiner-Bio-One, 
Frickenhausen, Germany 
Polyvinylidene fluoride membrane Carl Roth, Karlsruhe, 
Germany 
Polypropylene micro tubes 1.5 mL  
& 2 mL 
Sarstedt, Nümbrecht, 
Germany 
SealPlate®, multiwell plate cover seal Excel Scientific, 
Victorville, USA 
Screw-top micro caps Sarstedt, Nümbrecht, 
Germany 
Spatulas VWR, Darmstadt, 
Germany 
Square BioAssay Dish, 245 mm Corning, New York, 
USA 
Sterile filters Sartorius, Göttingen, 
Germany 
Sterile syringes B.Braun, Melsungen, 
Germany 
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Vivaflow® 200, crossflow module, 
100 kDa cut-off, polyethersulfone 
Sartorius, Göttingen, 
Germany 
 
2.1.3 Commercial kits und chromatography columns 
The commercial kits and chromatography columns used in 
this project are listed in the following table: 
 
Table 2-3 List of commercial kits and chromatography col-
umns used in this project 
Description Manufacturer 
Bio-Scale™ Mini Bio-Gel® P-6  
Desalting Cartridge 
Bio-Rad Laboratories, 
München, Germany 
Bio-Scale™ Mini UNOsphere  
Supra™ Cartridge 
Bio-Rad Laboratories, 
München, Germany 
Direct-zol™ RNA MiniPrep Plus Zymo Research, 
Freiburg, Germany 
Glucatell® Kit β-(1,3)-D-glucan  
detection 
Assoc. Cape Cod,  
Mörfelden-Walld., Ger. 
Hi Yield® Plasmid Mini DNA Kit Süd-Laborbedarf, Gauting, 
Germany 
Hi Yield® Gel/PCR DNA Fragment 
Extraction Kit 
Süd-Laborbedarf, Gauting, 
Germany 
NucleoBond® Xtra Midi Marcherey-Nagel, Düren, 
Germany 
NucleoSpin® Plasmid Marcherey-Nagel, Düren, 
Germany 
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NucleoSpin® Plasmid EasyPure Marcherey-Nagel, Düren, 
Germany 
  
NucleoSpin® Gel and PCR Clean-Up Marcherey-Nagel, Düren, 
Germany 
Superdex™ 75 HiLoad™ 16/60 GE Healthcare, München, 
Germany 
SuperScript™ IV First-Strand Synthe-
sis System 
Thermo Scientific, Dreieich, 
Germany 
Zeba™ Desalt Spin columns Thermo Scientific, Dreieich, 
Germany 
 
2.1.4 Chemicals and water 
The chemicals used in this project were purchased from the 
following manufacturers, if not mentioned otherwise: Appli-
Chem (Darmstadt, Germany), BD (Sparks, USA), Carl Roth 
(Karlsruhe, Germany), GE Healthcare (München, Germany), 
MBI FerŵeŶtas ;St. LeoŶ‐Rot, Germany), Merck (Darmstadt, 
GerŵaŶǇͿ, Riedel‐de Häen (Sarstedt, Germany), Roche 
(Mannheim, GermanyͿ, Fluka/Sigŵa‐AldriĐh ;Neu‐Ulŵ, Ger-
many) und Serva (Heidelberg, Germany).  
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Ultrapure water purified with the water installation arium66 
(Sartorious, Göttingen, Germany) was generally used in this 
project. 
2.1.5 Buffers and Solutions 
Buffers and solutions used in this project are listed in the fol-
lowing table: 
 
Table 2-4 List and composition of buffers or solutions used in 
this project 
Description                    Composition 
    
TAE buffer (pH 
8.0) 
40 
20 
2 
mM 
mM 
mM 
Tris 
Acetic acid 
Ethylenediaminetetraacetic acid 
Agarose gel  
1 
4.2 
 
% (w/v) 
µg L-1 
TAE buffer (solvent) 
Agarose 
Ethidium bromide 
Lowry reagent A 2 
0.4 
% (w/v) 
% (w/v) 
Na2CO3 
NaOH 
Lowry reagent B 1 % (w/v) CuSO4 x 5H2O 
Lowry reagent C 2 % (w/v) Sodium potassium tartrate  
tetrahydrate 
DNS reagent 1 
30 
 
1.6 
% (w/v) 
% (w/v) 
 
% (w/v) 
3,5-Dinitrosalicylic acid 
Sodium potassium tartrate tetra-
hydrate 
NaOH 
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5x Laemmli 
buffer (reduc-
ing) 
10 
500 
0.2 
15 
% (w/v) 
% (w/v) 
% (w/v) 
% (v/v) 
Sodium dodecyl sulfate  
Glycerol 
Bromophenol blue 
β-Mercaptoethanol 
5x Laemmli 
buffer (non-re-
ducing) 
10 
50 
0.02 
% (w/v) 
% (w/v) 
% (w/v) 
Sodium dodecyl sulfate  
Glycerol 
Bromophenol blue 
SDS-PAGE  
running buffer 
(pH 8.3) 
25 
192 
0.1 
mM 
mM 
% (w/v) 
Tris 
Glycin 
Sodium dodecyl sulfate 
Coomassie 
staining solution 
0.5 
10 
2.5 
% (w/v) 
% (v/v) 
% (v/v) 
Coomassie Brilliant Blue R250 
Acetic acid 
2-Propanol 
Blotting buffer 
(pH 8.3) 
25 
192 
mM 
mM 
Tris 
Glycin 
NBT 
 
30 
70 
g L-1 
%(v/v) 
Nitro blue tetrazolium chloride 
N,N-Dimethylformamide 
BCIP 15 
 
70 
g L-1 
 
%(v/v) 
5-Bromo-4-chloro-3-indolyl 
phosphate (diNa-salt) 
N,N-Dimethylformamide 
AP substrate 
buffer 
100 
0.5 
mM 
mM 
Tris 
MgCl2 
10 mM acetate 
buffer (pH 5.4)  
 Solutions of 10 mM acetate and 
10 mM sodium acetate mixed 
until a pH of 5.4 was reached. 
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PBS (phosphate 
buffered saline, 
pH 7.4) 
0.8 
0.02 
0.144 
0.024  
% (w/v) 
% (w/v) 
% (w/v) 
% (w/v) 
NaCl 
KCl 
Na2HPO4 x 2H2O 
KH2PO4 
PBST  
0.05 
 
% (v/v) 
PBS (solvent) 
Tween20 
MPBST  
2 
 
% (w/v) 
PBST (solvent) 
Milk powder 
TMB A (pH 4.1) 30 
50 
mM 
mM 
KCl 
Citric acid 
TMB B 90 
10 
0.3 
1 
% (v/v) 
% (v/v) 
% (v/v) 
mM 
Ethanol 
Acetone 
H2O2 
ϯ,ϯ’,ϱ,ϱ’-Tetramethylbenzidine 
TFB1 10 
30 
100 
50 
15 
mM 
mM 
mM 
mM 
% (v/v) 
CaCl2 
Potassium acetate 
RbCl 
MnCl2 
Glycerole 
TFB2 10 
50 
10 
15 
mM 
mM 
mM 
% (v/v) 
MOP 
CaCl2 
RbCl 
Glycerole 
Trypan blue  
solution 
 
0.4 
 
% (w/v) 
PBS (solvent) 
Trypan blue 
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Proteinase K 
buffer (pH 7.4) 
500 
1 
mM 
M 
CaCl2 
Tris 
5x Protein A 
binding buffer 
(pH 7.4) 
685 
13.5 
40.5 
21.5 
mM 
mM 
mM 
mM 
NaCl 
KCl 
KH2PO4 
Na2HPO4 
Protein A bind-
ing buffer 
137 
2.7 
8.1 
4.3 
mM 
mM 
mM 
mM 
NaCl 
KCl 
KH2PO4 
Na2HPO4 
His-tag binding 
buffer  
(pH 7.4) 
500 
20 
20 
10 
mM 
mM 
mM 
mM 
NaCl 
Na2HPO4 
NaH2PO4 
Imidazole 
His-tag elution 
buffer 
 
100 
 
mM 
PBS (solvent) 
Ethylenediaminetetraacetic acid 
Gel filtration 
buffer (pH 8) 
20 
150 
mM 
mM 
Tris 
NaCl 
Phage precipita-
tion solution 
20 
 
2.5 
% (v/v) 
 
M 
Polyethylene glycol (average mo-
lecular weight 6 kDa) 
NaCl 
Phage dilution 
buffer (pH 7.5) 
10 
20 
2 
mM 
mM 
mM 
Tris 
NaCl 
Ethylenediaminetetraacetic acid 
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If not mentioned otherwise, water was used as solvent and 
the pH was adjusted with 1 M HCl and 1 M NaOH. 
2.1.6 Media and Supplements 
Media and supplements used in this project are listed in the 
following table: 
 
Table 2-5 List and composition of media or supplements used 
in this project 
Description                    Composition 
    
2xYT-medium 1.6 
1.0 
0.5 
% (w/v) 
% (w/v) 
% (w/v) 
Bacto™ trypton 
Yeast extract 
NaCl 
Ampicillin 100 mg mL-1 Ampicillin 
Glucose 2 M Glucose 
IPTG 1 M IsopropǇl β-D-1-thiogalacto- 
pyranoside 
Kanamycin 10 mg mL-1 Kanamycin 
2xYT-A medium 100 µg mL-1 Ampicillin in 2xYT medium 
2xYT-AI medium 1 mM IPTG in 2xYT-A medium 
2xYT-GA medium 100 mM Glucose in 2xYT-A medium 
2xYT-KA medium 50 mg mL-1 Kanamycin in 2xYT-A medium 
2xYT-GA agar 1.5 % (w/v) Bacto™ Agar in 2xYT-GA 
medium 
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SOC medium 2 
0.5 
50 
10 
20 
% (w/v) 
% (w/v) 
% (w/v) 
mM 
mM 
Bacto™ trypton 
Yeast extract 
NaCl 
MgCl2 
Glucose 
Recovery medium   Purchased from Lucigen  
(Middleton, USA) 
FreeStyle™ F17-
medium 
  Purchased from Invitrogen  
(Darmstadt, Germany) 
HEK TF-medium   Purchased from Xell AG  
(Bielefeld, Germany) 
HEK cell culture 
medium 
 
 
25 
8 
0.1 
 
 
µg mL-1 
mM 
% (v/v) 
Freestyle™ F17-medium  
(solvent) 
G418 
L-glutamin 
Pluronic® (PAA Laboratories, 
Cölbe, Germany) 
HEK cell transfec-
tion medium 
 
 
8 
0.1 
 
 
mM 
% (v/v) 
Freestyle™ F17-medium  
(solvent) 
L-glutamin 
Pluronic® (PAA Laboratories, 
 Cölbe, Germany) 
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HEK cell feeding 
medium  
(for HEK293-6E) 
 
 
8 
0.1 
 
0.1 
 
 
mM 
% (v/v)  
 
% (w/v) 
Freestyle™ F17-medium (sol-
vent) 
L-glutamin 
Pluronic® (PAA Laboratories, 
Cölbe, Germany) 
Trypton N1 (PAA Laboratories, 
 Cölbe, Germany) 
HEK cell feeding 
medium  
(for EXPI293-F) 
 
8 
16 
 
mM 
% (v/v)  
HEK TF-medium (solvent) 
L-glutamin 
HEK FS (Xell AG, Bielefeld, 
Germany) 
 
All media and supplements were prepared with water as sol-
vent. 1 M HCl and 1 M NaOH were used for adjustment of 
pH. 
2.1.7 Glucans and other saccharides 
Glucans and other saccharides used in this project are listed 
in the following table: 
 
Table 2-6 List of glucans and saccharides used for the studies 
in this project 
Glucan Source 
  
β-(1,6)-D-Gentiobiose Carl Roth, Karlsruhe, 
Germany 
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Actigum CS 11 (Scleroglucan, lyophi-
lized) 
Degussa Construction Pol-
ymers, Trostberg, 
Germany 
Cinerean from Botrytis cinerea  
(LU 14548, 2 g L-1 in cell free culture  
supernatant, 5 g L-1 formic acid) 
U. Rau, TU Braunschweig, 
Braunschweig, Germany 
Dextran Pharmacia Fine chemi- 
cals, Uppsala, Sweden 
Fructigan from Monilinia fructigena 
(ATCC 24976, 4 g L-1 in cell free cul- 
ture supernatant, 5 g L-1 formic acid) 
U. Rau, TU Braunschweig, 
Braunschweig, Germany 
Laminarihexaose Megazyme, Wicklow,  
Ireland 
Laminarin Sigŵa AldriĐh, Neu‐Ulŵ, 
Germany 
Schizophyllan (lyophilized) Contipro Biotech, Dolní 
Doďrouč, CzeĐh RepuďlikͿ 
Schizophyllan from Schizophyllum 
commune (ATCC 38548, 5 g L-1 in cell 
free culture supernatant, 5 g L-1 fo- 
mic acid) 
U. Rau, TU Braunschweig, 
Braunschweig, Germany 
Scleroglucan from Sclerotium gl- 
canicum (DSM 2159, lyophilized) 
U. Rau, TU Braunschweig, 
Braunschweig, Germany 
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Scleroglucan from Sclerotium rolfsii 
culture (ATCC 15205, 5 g L-1 in cell 
free culture supernatant, 5 g L-1 for- 
mic acid) 
U. Rau, TU Braunschweig, 
Braunschweig, Germany 
Xanthan Carl Roth, Karlsruhe,  
Germany 
 
2.1.8 Commercial enzymes, buffers and molecular weight 
standards 
Commercial enzymes, buffers and molecular weight stand-
ards used in this project are listed in the following table: 
 
Table 2-7 List of commercial enzymes, buffers and molecular 
weight standards used in this project 
Description Manufacturer 
  
5x CutSmart® buffer New England Biolabs,  
Frankfurt a. M., Germany 
5x Green GoTaq® Reaction 
Buffer 
Promega, Madison, USA 
5x Phusion® HF Buffer Thermo Scientific,  
Dreieich, Germany 
25 mM MgCl2 Promega, Madison, USA 
Alkaline phosphatase, calf in-
testinal (CIP) 
New England Biolabs,  
Frankfurt a. M., Germany 
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BsiWI New England Biolabs,  
Frankfurt a. M., Germany 
BssHII New England Biolabs,  
Frankfurt a. M., Germany 
GeneRuler 1 kb Plus DNA Lad-
der 
Thermo Scientific,  
Dreieich, Germany 
GoTaq® DNA Polymerase Promega, Madison, USA 
HindIII-HF® New England Biolabs,  
Frankfurt a. M., Germany 
MluI-HF® New England Biolabs,  
Frankfurt a. M., Germany 
NcoI-HF® New England Biolabs,  
Frankfurt a. M., Germany 
NEBuffer™ 3.1 New England Biolabs,  
Frankfurt a. M., Germany 
NheI-HF® New England Biolabs,  
Frankfurt a. M., Germany 
NotI-HF®  New England Biolabs,  
Frankfurt a. M., Germany 
Phusion® High Fidelity DNA 
Polymerase 
Thermo Scientific,  
Dreieich, Germany 
Precision Plus Protein™ 
All Blue Prestained Standard 
Bio-Rad, München,  
Germany 
Precision Plus Protein™  
Unstained Standard 
Bio-Rad, München,  
Germany 
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Proteinase K Sigma Aldrich, Neu‐Ulŵ,  
Germany 
T4 DNA Ligase (HC) Promega, Madison, USA 
T4 DNA Ligase Buffer Promega, Madison, USA 
Trypsin Carl Roth, Karlsruhe,  
Germany 
 
2.1.9 Antibodies 
Antibodies used for analytics in this project are listed in the 
following table: 
 
Table 2-8 List of antibodies used for analytics in this project 
Antibody Description Source 
   
Goat anti-mouse IgG 
(Fc-specific, polycl- 
nal), AP conjugate 
115-055-071 Dianova, Hamburg, 
Germany 
Goat anti-mouse IgG 
(Fc-sepcific, polycl- 
nal), HRP conjugate 
A0168 Sigma Aldrich, München, 
Germany 
Mouse anti-c-myc-tag 9E10 AG Duebel, Braunschweig, 
Germany 
Mouse anti-His-tag DIA-900 Dianova, Hamburg,  
Germany 
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2.1.10 Plasmids 
Plasmids used for cloning in this project are listed in the fol-
lowing table: 
 
Table 2-9 List of plasmids used in this project 
Description Application 
  
pCSE2.6-mIgG2c-Fc-XP Expression vector for productionof  
scFv-Fc (murine Fc) in HEK cells 
pCSE2.5-Fab-h-HIS-XP Expression vector for production of  
Fab heavy chain in HEK cells 
pCSE2.5-Fab-k-HIS-XP Expression vector for production of 
Fab kappa light chain in HEK cells 
pHAL30 Phagemid vector for antibody library 
generation 
 
2.1.11 Oligonucleotides (primer) 
Oligonucleotides used in this project as primers for PCR ex-
periments are purchased from Biolegio B.V. (Nijmegen, 
Netherlands) and listed in the following table: 
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Table 2-10 List of oligonucleotides used in this project 
Description Oligonucleotide sequence Application 
   
JoJ48C11_VH_
BssHII_f 
TCCACAGGCGCGCACTCCG 
AGGTCCAGCTGCAACAATCT 
Fab cloning 
JoJ48C11_VH_
NheI_b 
TGGGCCCTTGGTGCTAGCTG 
AGGAGACTGTGAGAGTGGT 
Fab cloning 
JoJ48C11_VLK_
BssHII_f 
TCCACAGGCGCGCACTCCG 
ATATTGTGCTAACTCAGTCT 
Fab cloning 
JoJ48C11_VLK_
BsiWI_b 
TGGTGCAGCCACCGTACGT 
TTCAGCTCCAGCTTGGTCCC 
Fab cloning 
JoJ48C11-VH-
D105A-f 
GGTACTGCCTACTGGGGCC 
AAGGCAC 
Point mutation 
JoJ48C11-VH-
D105A-b 
CCAGTAGGCAGTACCCAGG 
GGCCATAG 
Point mutation 
JoJ48C11-VH-
E59A-f 
GGTTATACTGCATACAATC 
AGAAGTTCAAGGAC 
Point mutation 
JoJ48C11-VH-
E59A-b 
CTGATTGTATGCAGTATAA 
CCAGTGCTAGG 
Point mutation 
JoJ48C11-VH-
H35A-f 
CTACTGGATGGCCTGGGT 
AAAACAGAGGCCTG 
Point mutation 
JoJ48C11-VH-
H35A-b 
GTTTTACCCAGGCCATCCA 
GTAGCTAGTAAAG 
Point mutation 
JoJ48C11-VH-
S31A-f 
CTTTACTGCCTACTGGATG 
CACTGGG 
Point mutation 
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JoJ48C11-VH-
S31A-b 
CCAGTAGGCAGTAAAGGT 
GTAGCCAG 
Point mutation 
JoJ48C11-VH-
W33A-f 
CTAGCTACGCAATGCACTG 
GGTAAAACAGAGG 
Point mutation 
JoJ48C11-VH-
W33A-b 
CAGTGCATTGCGTAGCTAG 
TAAAGGTGTAGCC 
Point mutation 
JoJ48C11-VH-
W47A-f 
GGTCTGGAAGCAATTGGAT 
ACATTAATCC 
Point mutation 
JoJ48C11-VH-
W47A-b 
GTATCCAATTGCTTCCAGAC 
CCTGTCCAG 
Point mutation 
JoJ48C11-VH-
W100A-f 
CCCCTAGCACCCCTGGGTA 
CTGAC 
Point mutation 
JoJ48C11-VH-
W100A-b 
CAGGGGTGCTAGGGGTGC 
ACAGTAATAG 
Point mutation 
JoJ48C11-VH-
Y27A-f 
CTTCTGGCGCAACCTTTACT 
AGCTACTGGATG 
Point mutation 
JoJ48C11-VH-
Y27A-b 
GTAAAGGTTGCGCCAGAA 
GCCTTGCAGG 
Point mutation 
JoJ48C11-VH-
Y50A-f 
GATTGGAGCAATTAATCCT 
AGCACTGG 
Point mutation 
JoJ48C11-VH-
Y50A-b 
GATTAATTGCTCCAATCCAT 
TCCAGACCC 
Point mutation 
JoJ48C11-VH-
Y57A-f 
CACTGGTGCAACTGAGTAC 
AATCAGAAG 
Point mutation 
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JoJ48C11-VH-
Y57A-b 
CTCAGTTGCACCAGTGCTA 
GGATTAATG 
Point mutation 
JoJ48C11-VL-
D49A-f 
GGATTTATGCCACATCCAAA 
CTGGC 
Point mutation 
JoJ48C11-VL-
D49A-b 
GGATGTGGCATAAATCCAT 
CTTTTGG 
Point mutation 
JoJ48C11-VL-
K52A-f 
CACATCCGCACTGGCTTCTG 
GAGTCC 
Point mutation 
JoJ48C11-VL-
K52A-b 
GAAGCCAGTGCGGATGTGT 
CATAAATCC 
Point mutation 
JoJ48C11-VL-
N93A-f 
GGAGTAGTGCACCACCCAC 
GTTCGGTG 
Point mutation 
JoJ48C11-VL-
N93A-b 
GTGGGTGGTGCACTACTCC 
ACTGCTGG 
Point mutation 
JoJ48C11-VL-
S55A-f 
CTGGCTGCAGGAGTCCCTG 
CTCG 
Point mutation 
JoJ48C11-VL-
S55A-b 
GACTCCTGCAGCCAGTTTG 
GATGTG 
Point mutation 
JoJ48C11-VL-
W90A-f 
GCCAGCAGGCAAGTAGTAA 
CCCACCCACG 
Point mutation 
JoJ48C11-VL-
W90A-b 
GTTACTACTTGCCTGCTGGC 
#AGTAATAAGTGG 
Point mutation 
MHC.F GGCCAGTGGATAGTCAGAT 
GGGGGTGTCGTTTTGGC 
Library con-
struction 
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MHC.F.Hind GGCCAGTGGATAAAGCTTT 
GGGGGTGTCGTTTTGGC 
Library con-
struction 
MhgIII_r CTAAAGTTTTGTCGTCTTT 
CC 
Colony PCR and  
Sequencing 
MHLacZ-Pro_f GGCTCGTATGTTGTGTGG Colony PCR 
MHV.B1 GATGTGAAGCTTCAGGAG 
TC 
Library con-
struction 
MHV.B1.Nco GAATAGGCCATGGCGGAT 
GTGAAGCTTCAGGAGTC 
Library con-
struction 
MHV.B2 CAGGTGCAGCTGAAGGA 
GTC 
Library con-
struction 
MHV.B2.Nco GAATAGGCCATGGCGCAG 
GTGCAGCTGAAGGAGTC 
Library con-
struction 
MHV.B3 CAGGTGCAGCTGAAGCAG 
TC 
Library con-
struction 
MHV.B3.Nco GAATAGGCCATGGCGCAG 
GTGCAGCTGAAGCAGTC 
Library con-
struction 
MHV.B4 AGGTTACTCTGAAAGAGTC 
 
Library con-
struction 
MHV.B4.Nco GAATAGGCCATGGCGCAG 
GTTACTCTGAAAGAGTC 
Library con-
struction 
MHV.B5 GAGGTCCAGCTGCAACAA 
TCT 
Library con-
struction 
MHV.B5.Nco GAATAGGCCATGGCGGAG 
GTCCAGCTGCAACAATCT 
Library con-
struction 
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MHV.B6 GAGGTCCAGCTGCAGCAG 
TC 
Library con-
struction 
MHV.B6.Nco GAATAGGCCATGGCGGAG 
GTCCAGCTGCAGCAGTC 
Library con-
struction 
MHV.B7 GAGGTGAAGCTGGTGGAG 
TC 
Library con-
struction 
MHV.B7.Nco GAATAGACCATGGCGCAG 
GTCCAACTGCAGCAGCCT 
Library con-
struction 
MHV.B8 GAGGTGAAGCTGGTGGA 
GTC 
Library con-
struction 
MHV.B8.Nco GAATAGGCCATGGCGGAG 
GTGAAGCTGGTGGAGTC 
Library con-
struction 
MHV.B9 GAGGTGAAGCTGGTGGA 
ATC 
Library con-
struction 
MHV.B9.Nco GAATAGGCCATGGCGGAG 
GTGAAGCTGGTGGAATC 
Library con-
struction 
MHV.B10 GATGTGAACTTGGAAGTG 
TC 
Library con-
struction 
MHV.B10.Nco GAATAGGCCATGGCGGAT 
GTGAACTTGGAAGTGTC 
Library con-
struction 
MHV.B12 GAGGTGCAGCTGGAGGA 
GTC 
Library con-
struction 
MHV.B12.Nco GAATAGGCCATGGCGGAG 
GTGCAGCTGGAGGAGTC 
Library con-
struction 
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MKC.F GGATACAGTTGGTGCAGCA 
TC 
Library con-
struction 
MKC.F.Not TGACAAGCTTGCGGCCGCG 
GATACAGTTGGTGCAGCATC 
Library con-
struction 
MKV.B1 GATGTTTTGATGACCCAAA 
CT 
Library con-
struction 
MKV.B1.Mlu TACAGGATCCACGCGTAGA 
TGTTTTGATGACCCAAACT 
Library con-
struction 
MKV.B2 GATATTGTGATGACGCAGG 
CT 
Library con-
struction 
MKV.B2.Mlu TACAGGATCCACGCGTAGA 
TATTGTGATGACGCAGGCT 
Library con-
struction 
MKV.B3 GATATTGTGATAACCCAG 
 
Library con-
struction 
MKV.B3.Mlu TACAGGATCCACGCGTAGA 
TATTGTGATAACCCAG 
Library con-
struction 
MKV.B4 GACATTGTGCTGACCCAAT 
CT 
Library con-
struction 
MKV.B4.Mlu TACAGGATCCACGCGTAGA 
CATTGTGCTGACCCAATCT 
Library con-
struction 
MKV.B5 GACATTGTGATGACCCAGT 
CT 
Library con-
struction 
MKV.B5.Mlu TACAGGATCCACGCGTAGA 
CATTGTGATGACCCAGTCT 
Library con-
struction 
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MKV.B6 GATATTGTGCTAACTCAGT 
CT 
Library con-
struction 
MKV.B6.Mlu TACAGGATCCACGCGTAG 
ATATTGTGCTAACTCAGTCT 
Library con-
struction 
MKV.B7 GATATCCAGATGACACAGA 
CT 
Library con-
struction 
MKV.B7.Mlu TACAGGATCCACGCGTAGA 
TATCCAGATGACACAGACT 
Library con-
struction 
MKV.B8 GACATCCAGCTGACTCAGT 
CT 
Library con-
struction 
MKV.B8.Mlu TACAGGATCCACGCGTAGA 
CATCCAGCTGACTCAGTCT 
Library con-
struction 
MKV.B9 CAAATTGTTCTCACCCAG 
TCT 
Library con-
struction 
MKV.B9.Mlu TACAGGATCCACGCGTACA 
AATTGTTCTCACCCAGTCT 
Library con-
struction 
MKV.B10 GACATTCTGATGACCCAGT 
CT 
Library con-
struction 
MKV.B10.Mlu TACAGGATCCACGCGTAGA 
CATTCTGATGACCCAGTCT 
Library con-
struction 
MLC.F GGTGAGTGTGGGAGTGGA 
CTTGGGCTG 
Library con-
struction 
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MLC.F.Not TGACAAGCTTGCGGCCGCG 
GTGAGTGTGGGAGTGGACT 
TGGGCTG 
Library con-
struction 
MLV.B CAGGCTGTTGTGACTCAG 
GAA 
Library con-
struction 
MLV.B.Mlu TACAGGATCCACGCGTACA 
GGCTGTTGTGACTCAGGAA 
Library con-
struction 
Tor-pCMV-
mIgG01-FC- 
seq-f 
CACTTTGCCTTTCTCTCC Colony PCR 
Tor-pCMV-
mIgG01-FC- 
seq-r 
CAGATGGCTGGCAACTAG Colony PCR 
ToR-pCMV- 
Seq-f 
TGGTAGCAACAGCTACAG Sequencing 
 
2.1.12 E. coli strains, bacteriophage, mammalian cell line 
and mice 
Organisms used in this project are listed in the following ta-
ble: 
 
Table 2-11 List of organisms used in this project 
Description Genotype or properties Source 
   
BALB/c mice Inbred mouse strain,  
female, 7 weeks old 
TU Braunschweig, 
Braunschweig, 
Germany 
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E. coli XL1-Blue 
MRF’ 
Δ;mcrAͿϭϴϯ, Δ;mcrCB-
hsdSMR-mrr)173, endA1, 
supE44, thi-1, recA1, 
gyrA96, relA1, lac [F’ proAB, 
laclqZΔMϭϱ, TŶϭϬ (Tetr)] 
Stratagene, La 
Jolla, 
USA 
E. cloni® 10G  
Surpreme 
F- mcrA Δ;mrr-hsdRMS-
mcrBC) endA1 recA1 
ΦϴϬdlacZΔMϭϱ 
ΔlacX74 araD139 
Δ;ara,leu)7697 
galU galK rpsL nupG 
λ- tonA (StrR) 
Lucigen, Middle-
ton,USA 
ER2738 [F'proA+B+ lacIq 
Δ;lacZͿMϭ5 zzf::TnϭϬ 
(Tetr)] fhuAϮ glnVΔ;lac- 
proAB) thi-ϭΔ;hsdS-mcrB)5 
Lucigen, Middle-
ton,USA 
EXPI293-F™ Human embryonic kid- 
neycells, suspension  
cell line 
Thermo Scientific, 
Dreieich, Germany 
HEK293-6E Human embryonic kid- 
ney cells, suspension 
cell line 
NRC Biotechnology 
Research Institute, 
Montreal, Canada 
Hyperphage M13K07 Helper phage  
with deletion of pIII 
Progen Biotechnik 
GmbH, Heidelberg, 
Germany 
M13K07 Helper phage J. Vieira and  
J. Messing [50] 
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2.1.13 Software and databases 
Software and databases used for this project are listed in the 
following table: 
 
Table 2-12 List of Software and databases used for this pro-
ject 
Description Source/Manufacturer Application 
   
CCP4MG 2.10.6 University of New York,  
New York, USA 
Structure data 
visualization 
Gen5 2.08 BioTek Instruments,  
Winooski, USA 
ELISA plate doc-
umentation 
Geneious 4.8.5 Biomatters Ltd, Auckland, 
New Zealand 
Sequence data 
analysis and 
processing 
IMGT/V-QUEST http://www.imgt.org Antibody se- 
quence analysis 
Intas GDS Intas, Göttingen, Germany Agarose gel  
documentation 
Liquid Handling 
Control 2.17 
BioTek Instruments, Winoo-
ski, USA 
Controlling of 
liquid handling 
system EL 406 
Mendeley Desk-
top 
Mendeley Ltd, London, UK  Literature data-
base and cita- 
tion 
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Microsoft Office 
2010 
Microsoft, Redmond, USA Text, Calcula-
tion and Draw- 
ing 
NanoDrop ND-
1000 
Coleman Technologies, Or-
lando, USA 
DNA and pro-
tein concentra- 
tion analysis 
NCBI http://www.ncbi.nlm.nih.gov/ Literature  
research 
Scopus https://www.sco-
pus.com/home.uri 
Literature  
research 
Sigma Plot 12.3 Systat Software, Erkrath, Ger-
many 
Calculation and 
data presenta- 
tion 
UNICORN GE Healthcare, München, 
Germany 
Controlling of 
ÄKTApurifier 
VBASE2 http://www.vbase2.org Antibody se- 
quence analysis 
 
2.2 Methods 
2.2.1 Sterilization 
Sterilization of liquids and unsterile consumables as well as 
inactivation of biological material were done by autoclaving 
each separately for at least 20 minutes at 121 °C with 1 bar 
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overpressure. Heat sensitive substances were filtered by a 
0.2 µm filter into sterile vessels under sterile conditions. 
2.2.2 Molecular biological methods 
The following molecular biological methods were used in 
this project. 
2.2.2.1 Preparation of DNA 
Plasmid DNA from E. coli cultures was isolated with commer-
cial plasmid DNA preparation kits according to their manu-
als. PCR-products and DNA-fragments were purified either 
from the reaction mix or from agarose gels with a commer-
cial PCR clean up and gel extraction kits. The purified DNA 
was solubilized in water and stored at -20 °C. 
2.2.2.2 Determination of DNA concentrations by spectro-
photometry 
The concentration of DNA preparations was determined by 
measuring the absorbance at λ = ϮϲϬ nm with a spectropho-
tometer and were calculated by the correlation A260 = 1 ≙ 
1 ng µL-1. 
2.2.2.3 Fragmentation of DNA with endonucleases 
Insert isolation and vector linearization for cloning were per-
formed by treatment with commercial endonucleases. In 
general, 1 µg of DNA was fragmented with one or a 
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combination of two commercial endonucleases (1 µL each) 
in 50 µL of the recommended buffer. After incubation the 
enzymes were inactivated for 20 minutes at 80 °C. 
2.2.2.4 Dephosphorylation of linearized vector DNA 
The ligation of linearized vector DNA with itself was pre-
vented by adding 1 µL (5 U) of calve intestinal phosphatase 
(CIP) to the endonuclease reaction mix during incubation. 
2.2.2.5 Ligation of vector DNA with insert DNA 
The construction of functional plasmids from linearized vec-
tor DNA and insert DNA was performed by ligation with com-
mercial T4 DNA Ligase. Therefore, 50 ng of the linearized 
vector DNA was mixed with insert DNA in a molar ratio of 
one to three in 20 µL of T4 ligation buffer. 0.5 µL of T4 DNA 
ligase was added and the reaction mix was incubated for 30 
minutes at 20 °C (room temperature) or overnight at 16 °C. 
If necessary the ligase was heat inactivated by incubation at 
70 °C for 10 minutes. 
2.2.2.6 Polymerase chain reaction (PCR) 
The DNA amplification by PCR were performed to control for 
correct plasmid construction or to introduce changes in DNA 
sequences. 
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Colony PCR 
Insert rates and correct insert size after cloning and transfor-
mation were controlled via colony PCR with primers flanking 
the cloning sites of the vectors. A small amount of E. coli 
cells, either a colony from an agar plate or less than 1 µL 
from a liquid culture, were added to 10 µL of the reaction 
mix. The mixture was incubated in a thermocycler with the 
appropriate temperature program. The reaction mix was 
used for agarose gel electrophoresis after PCR. 
 
Table 2-13 Reaction mix for colony PCR 
Stock solution 
Volumes [µL] per 10 
µL reaction mix 
  
5x Green GoTag® Reaction Buffer 2.0 
25 mM MgCl2 0.8 
10 mM dNTP mix 0.2 
10 mM forward primer 0.5 
10 mM reverse primer 0.5 
5 U µL-1 GoTag® DNA Polymerase 0.05 
Water 5.95 
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Table 2-14 Temperature profile for colony PCR 
Step Profile Repeats 
   
1. Initial denaturation 95 °C for 2 minutes x1 
2. Denaturation 94 °C for 15 seconds 
 x25 
3. Annealing 56 °C for 20 seconds 
4. Elongation 72 °C for 30 seconds per 
kbp insert 
5. Final Elongation 72° C for 3 Minutes x1 
6. Store 16 °C forever  
 
 
PCR for Fab construction 
Separation of the VH and VL sequence segments from 
pHAL30-JoJ48C11 and introduction of new endonuclease 
recognition sites were performed by PCR. The amplificated 
segments were isolated by agarose gel electrophoresis and 
used for cloning after gel extraction. 
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Table 2-15 PCR reaction mix for Fab construction 
Stock solution 
Volumes [µL] per 100 
µL reaction mix 
  
5 ng µL-1 pHAL30-JoJ48C11 1.0 
5x Green GoTag® Reaction Buffer 20.0 
25 mM MgCl2 6.0 
10 mM dNTP mix 2.0 
10 mM forward primer 2.0 
10 mM reverse primer 2.0 
5 U µL-1 GoTag® DNA Polymerase 0.5 
Water 66.0 
 
 
Table 2-16 PCR temperature profile for Fab construction 
Step Profile Repeats 
   
1. Initial denaturation 95 °C for 2 min x1 
2. Denaturation 95 °C for 15 s 
 x25 3. Annealing 56 °C for 20 s 
4. Elongation 72 °C for 2.5 min 
5. Final Elongation 72° C for 3 min x1 
6. Store 16 °C forever  
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Quick change PCR 
The exchange of codons in antibody sequences was per-
formed via quick change PCR. Therefore, the whole plasmid 
carrying the antibody sequence was amplified with ϯ’-over-
lapping primers which have the new codon integrated on the 
desired position.[56] After PCR the methylated template 
was erased by addition of 1 µL of the endonuclease DpnI to 
the reaction and incubation for 1 hour at 37 °C. 10 µL of the 
reaction mix was directly used for heat shock transfor-
ŵatioŶ. The liŶear PCR produĐt had oǀerlappiŶg ϯ’-over-
hangs which resulted to stabile circularization. The nicked 
plasmid was repaired inside the E. coli cells by homologous 
recombination. 
 
Table 2-17 Reaction mix for quickchange PCR 
Stock solution 
Volumes [µL] per 
25 µL reaction mix 
  
0.5 ng µL-1 pCSE2.6-mIgG2c-Fc-JoJ48C11 1.0 
5x Phusion® HF Reaction Buffer 5.0 
10 mM dNTP mix 0.5 
10 mM forward primer 1.25 
10 mM reverse primer 1.25 
5 U µL-1 Phusion® High Fidelity DNA Poly-
merase 
0.25 
Water 15.75 
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Table 2-18 Temperature profile for quick change PCR 
Step Profile Repeats 
   
1. Initial denaturation 98 °C for 30 s x1 
2. Denaturation 98 °C for 10 s 
 x5 
3. Annealing (part I) 72 °C for 2 s 
4. Annealing (part II) Ramp of 1 °C s-1 to 64 °C 
5. Annealing (part III) 64 °C for 10 s 
6. Elongation 72 °C for 2 min 
7. Denaturation 98 °C for 10 s 
 x20 
8. Annealing & Elongation 72 °C for 2 min 
9. Final Elongation 72° C for 5 min x1 
10. Store 16 °C forever  
 
2.2.2.7 Agarose gel electrophoresis 
Samples were filled into wells of an agarose gel that was in-
side of electrophoresis chamber filled with TAE buffer. The 
separation of DNA fragments was done by electrophoresis 
for 25 – 30 minutes with a constant voltage of 120 V. The 
result of separation was documented by UV radiation of the 
agarose gel. 
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2.2.2.8 DNA sequencing 
DNA sequencing was performed by the Sanger sequencing 
service from Seqlab Sequence Laboratories GmbH (Göttin-
gen, Germany) after providing purified plasmid DNA. 
2.2.3 Biochemical methods 
The following biochemical methods were used in this pro-
ject. 
2.2.3.1 Determination of protein concentrations by spec-
trophotometry 
The concentration of purified proteins was determined by 
ŵeasuriŶg the aďsorďaŶĐe at λ = ϮϴϬ nm with a spectropho-
tometer. With their respective molecular weight and molar 
absorption coefficient the concentration was calculated via 
the lambert beer law. 
2.2.3.2 Determination of protein concentrations with 
Lowry protein assay 
The protein concentration in aqueous glucan solutions was 
determined spectro-photometrical with the Lowry protein 
assay [57]. 100 µL of the sample was mixed with 1 mL of 
freshly prepared Lowry reagent E (100 vol. Lowry reagent A, 
1 vol. Lowry reagent B and 1 vol. Lowry reagent C) and incu-
bated for 5 minutes at room temperature in the dark. 100 µL 
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of fresh prepared ϱϬ % ;ǀ/ǀͿ FoliŶ & CioĐalteu’s pheŶol rea‐
gent was added and the solution was instantly mixed. After 
an additional incubation for 30 minutes in the dark, the ab-
sorption of the mixture was ŵeasured ǁith a photoŵeter ;λ 
= 660 nm). Water was used as blind and 50 mg L-1, 
100 mg L-1, 150 mg L-1, 200 mg L-1 and 250 mg L-1 solutions 
of bovine serum for calibration. 
2.2.3.3 Determination of glucan concentrations by 2-pro-
panol precipitation 
The gravimetric determination of the glucans was carried 
out by precipitation with 2-propanol. 5 mL of aqueous glu-
can solution was mixed with 15 mL of cold 2-propanol and 
stored overnight at 4 °C. The solution with the precipitated 
glucan was transferred into a pre-weighed metallic centri-
fuge tube and centrifuged for 15 minutes with 13,000 xg at 
4°C. The supernatant was discarded and the glucan pellet 
was dried for 48 hours at 50 °C in a vacuum oven. After cool-
ing down to room temperature in a desiccator, the tube was 
weighed and the glucan concentration was calculated from 
the mass difference. 
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2.2.3.4 Determination of glucose concentration with di-
nitrosalicylic acid (DNS) 
The glucose concentration in aqueous glucan solutions was 
determined spectro-photometrical with DNS. Therefore, 1 
mL of glucan solution was mixed with 1 mL water and 2 mL 
of DNS reagent. The mixture was incubated in a water bath 
at 95°C for 15 minutes and instantly transferred to an ice 
bath. After 5 minutes of cooling down, the mixture was 
stored for 10 minutes at room temperature before its ab-
sorption was measured ;λ = ϲϲϬ ŶŵͿ. Water ǁas used as 
blind and 0.1 g L-1, 0.2 g L-1, 0.3 g L-1, 0.4 g L-1, 0.6 g L-1, 
0.8 g L-1 and 1.0 g L-1 solutions of D-glucose for calibration. 
2.2.3.5 Determination of Schizophyllan concentration via 
Glucatell® kit 
The determination of Schizophyllan concentration was car-
ried out with the β-(1,3)-D-glucan sensitive Glucatell® kit 
from Asocciates of Cape Cod, Inc. (Mörfelden-Walldorf, Ger-
many). It is based on Limulus amebocyte lysate (LAL) from 
horseshoe crabs which reacts with β-(1,3)-D-glucans by acti-
vation of a clotting enzyme that cleaves a chromogenic pep-
tide. The analysis was performed according to the end-point 
assay manual but with bisected volumes of used reagents 
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and samples. The absorption of the freed and diazotized 
chromogen was measured at 540 nm.  
2.2.3.6 Sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) 
Analysis of proteins for purity and correct molecular weight 
was performed by SDS-PAGE. Therefore, the discontinuous 
SDS-PAGE was applied as described by Laemmli [58] with a 
separation gel overlaid with a stacking gel. Samples were 
prepared by heating 20 µL for 5 minutes at 95 °C with 5 µL 
reducing 5x Laemmli buffer or 65 °C with 5 µL of non-reduc-
ing 5x Laemmli buffer. The samples were loaded into the 
wells of the stacking gel and the proteins were separated by 
electrophoresis in SDS-PAGE running buffer for 45 - 50 
minutes with a constant voltage of 200 V. After the electro-
phoresis the gel was stained or used for immunoblot. 
 
Table 2-19 Composition of the stacking gel 
Stock solution Volume per 4% gel 
  
Water 1.0 mL 
30 % (w/v) Acrylamide/Bis 260 µL 
1 M Tris-HCl, pH 6.8 200 µL 
10 % (w/v) SDS 15 µL 
10 % Ammonium persulfate 15 µL 
N,N,N′,N′-Tetramethylethane-1,2-diamine 2 µL 
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Table 2-20 Composition of the separation gels 
Stock solution 
Volume per 
12% gel 
Volume per 
15% gel 
   
Water 1.3 mL 900 µL 
30 % (w/v) Acrylamide/Bis 1.6 mL 2.0 mL 
1.5 M Tris-HCl, pH 8.8 1.0 mL 1.0 mL 
10 % (w/v) SDS 40 µL 40 µL 
10 % Ammonium persulfate 40 µL 40 µL 
N,N,N′,N′-Tetramethylethane 
-1,2-diamine 
2 µL 2 µL 
 
2.2.3.7 Coomassie staining of polyacrylamide gels 
The polyacrylamide gel from the SDS-PAGE was submerged 
in Coomassie staining solution and heated in a microwave 
oven until the gel was completely stained. In the next step 
the gel was destained by heating and incubation in aqueous 
10 % (v/v) acetic acid until the gel was destained and protein 
bands were clearly visible. 
2.2.3.8 Immunoblot 
Immunoblot was performed for the detection of specific 
proteins inside of a sample. Therefore, the proteins of a sam-
ple were separated by SDS-PAGE. A PVDF membrane was ac-
tivated by submerging in ethanol and was rinsed with 
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blotting buffer. The membrane was placed onto a filter pa-
per that was soaked with running buffer. Onto the mem-
brane the gel was overlaid and this was covered with an-
other soaked filter paper. The proteins in the gel were blot-
ted onto the PVDF membrane with a blotting device (20 V, 
35 minutes). The membrane was blocked with 10 mL MPBST 
for 1 hour at room temperature. The primary antibody 9E10 
(1:500 in 10 mL MPBST) was added to the membrane. After 
1 hour it was washed two times with 20 mL PBST and the 
secondary antibody 115-055-071 (AP conjugate, 1:30,000 in 
10 mL MPBST) was added for another hour of incubation. It 
was washed again two times with 20 mL PBST. The devel-
oper solution (100 µL NBT and 100 µL BCIP in 10 mL AP sub-
strate buffer) was added to the membrane. The blot was de-
veloped without rocking until clear bands from the protein 
of interest became visible. Afterwards the membrane was 
washed extensively with water and was dried with paper 
towels. 
2.2.3.9 Immobilization of Schizophyllan at hydroxyl func-
tionalized magnetic beads 
The methodic approach was nearly the same as described by 
Sun et al. [59]. 0.5 mL of epoxy-coated magnetic beads 
(Dynabeads® M-270 Epoxy; 15 mg mL-1 in DMF) was washed 
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three times with 0.5 mL 100 %(v/v) ethanol. The surface was 
functionalized with hydroxy-groups attached by incubation 
in 0.5 mL 20 mM 4-Hydroxybenzhydrazide in anhydrous N,N-
Dimethylformamide for 10 h under gentle shaking at 37 °C. 
The modified beads were washed three times with 0.5 mL 
100 %(v/v) ethanol and were stored in 0.5 mL 100 %(v/v) 
ethanol at 4°C. For immobilization a respective amount of 
modified bead suspension was washed three times with 
0.2 mM sodium acetate buffer (pH 5.4) and was incubated 
overnight in 0.2 mM sodium acetate buffer with glucan at 
37 °C over night. Glucan which did not bind to the beads was 
removed by washing three times with 0.2 mM sodium ace-
tate buffer. The glucan conjugated beads were stored in PBS 
containing 0.2 g L-1 NaN3 until use. Prior to usage the glucan 
conjugated beads were washed three times with water. 
2.2.3.10 Immobilization of Schizophyllan at hydrazide func-
tionalized magnetic beads 
The methodic approach was nearly the same as described by 
Park et al. [60]. 0.25 mL of amine-coated magnetic beads 
(Dynabeads® M-270 Amine; 30 mg mL-1 in N,N-Dimethylfor-
mamide) was washed three times with 0.5 mL N,N-Dimethyl-
formamide (DMF) and resuspended in 3 % (w/v) succinic an-
hydride (in DMF). After 3 h incubation at room temperature 
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under gentle shaking, the beads were washed again three 
times with 0.5 mL N,N-dimethylformamide (DMF). The next 
steps involved: 3 h incubation in 0.5 mL 3 % (w/v) N-hydroxy-
succinimide + 3 % (v/v) diisopropylcarbodiimide (in DMF) at 
room temperature; three times washing with 0.5 mL DMF; 
3 h incubation in 0.5 mL 3 % (v/v) 4,7,10-trioxa-1,3-tridecan-
diamin (in DMF) at RT; three times washing with 0.5 mL 
DMF; 3 h incubation in 0.5 mL 3 % (w/v) succinic anhydride 
(in DMF) at RT; three times washing with 0.5 mL DMF; 3 h 
incubation in 0.5 mL 3 % (w/v) N-hydroxysuccinimide + 3 
% (v/v) diisopropylcarbodiimide (in DMF) at room tempera-
ture; 3 times washing with DMF; and 3 h incubation in 0.5 mL 
3 % (v/v) hydrazine monohydrate at room temperature. Af-
ter additional washing with 0.5 mL DMF, the beads were 
stored in 0.5 mL DMF at 4 °C. For immobilization a respective 
amount of modified bead suspension was washed three 
times with PBS (pH adjusted to 5.0) and was incubated over-
night in PBS (pH 5.0) with glucan and 30 % (v/v) glycerol at 
50 °C. Glucan which did not bind to the beads was removed 
by washing three times PBS (pH 7.4). The glucan conjugated 
beads were stored in PBS containing 0.2 g L-1 NaN3 until use. 
Prior to usage the glucan conjugated beads were washed 
three times with water. 
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2.2.3.11 Coating of Carbo-BIND™ 96-Well plates 
For the antibody selection and ELISA experiments, Schizo-
phyllan was immobilized to Carbo-BIND™ multiwell plates. 
The wells were filled with 100 µL of 10 µg mL-1 SCH-PK in 
10 mM acetate buffer (pH 5.4) and the sealed plates were 
incubated at 37 °C overnight. The following day the wells 
were washed 10 times with water and filled for storage with 
300 µL PBS containing 0.2 g L-1 NaN3 until use. 
2.2.3.12 Enzyme-linked immunosorbent assay (ELISA) 
Analytics of the recombinant antibodies for their binding 
properties were generally performed by ELISA experiments. 
 
Titration ELISA 
The half maximal effective concentration (EC50) values of 
the produced rAbs was determined by titration ELISA using 
serial dilutions of the antibodies. The SCH-PK loaded Carbo-
BIND™ plate was blocked with MPBST for 1 hour at room 
temperature. The blocking solution was discarded and 
100 µL of the rAbs (dilution series in blocking solution) were 
filled into the wells. After 1 hour incubation, the plate was 
washed for 3 times with PBST or 0.05% (w/v) Tween20.  Af-
terwards, 100 µL well-1 peroxidase-conjugated goat anti-mu-
rine Fc antibody (1:40,000 in MPBST) was added and 
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incubated for an additional hour. The plate was then washed 
again for 3 times. The color reaction was obtained by adding 
100 µL well-1 freshly mixed TMB (20 volume TMB A and 1 
volume TMB B). The reaction was stopped after 10-15 min 
by addition of 100 µL well-1 of 0.5 mol L-1 H2SO4. The resulting 
absorption was measured at 450 nm (reference wavelength 
620 nm).  
For antibodies in the Fab format, an additional incubation 
step with 100 µL well-1 of an anti-His-tag murine antibody 
(40 ng mL-1) was necessary before the peroxidase conju-
gated antibody was added. 
The EC50 was derived from a regression of absorbance signal 
against the logarithm of antibody concentration by a sig-
moidal function with 3 parameters. 
 
Competitive ELISA 
Antigen specificity was evaluated via competition of scFv-Fc 
binding to immobilized SCH-PK by various soluble saccha-
rides. Each scFv-Fc was used in the concentration that re-
sulted in 40 % of the saturation signal in the titration ELISA. 
They were preincubated with serial dilutions of competitors 
solved in MPBST for 1 h before transfer to the SCH-PK loaded 
Carbo-BIND™ plate. The further procedure and the analytics 
of the results were executed as described for titration ELISA.  
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2.2.4 Microbiological methods 
The following microbiological methods were used frequently 
in this project. 
2.2.4.1 Cultivation of Escherichia coli (E. coli) on plates 
E. coli suspension from transformation or phage infection 
was plated with a spatula onto 2xYT-GA agar in a petri dish. 
The plate was incubated overnight at 37 °C. 
2.2.4.2 Cultivation of E. coli in liquid cultures 
Cultivation of E. coli for phage infection or plasmid amplifi-
cation was performed in suspension culture. Therefore, the 
required volume of 2xYT medium with the respective sup-
plements was inoculated with E. coli cells from a cryo con-
served culture, with a colony from a plate or with cell sus-
pension of a pre-culture. The suspension was incubated in a 
shake incubator at 37 °C and 250 rpm overnight or until the 
desired cell density was reached. The cell density of the cul-
ture was measured as optical density (OD) in a photometer 
with λ = 600 nm. 
2.2.4.3 Cryo conservation of E. coli 
Long time storage of E. coli cells was performed by supple-
menting liquid culture with 30 % (w/v) glycerol and keeping 
the culture at -80 °C. 
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2.2.4.4 Preparing chemically competent E. coli cells 
Chemically competent E. coli cells for heat shock transfor-
mation were prepared from a liquid culture of E. coli XL1-
ďlue MRF’ in the exponential growth phase (OD600 = 0.5). 
100 mL culture was centrifuged for 10 minutes with 3,220 xg 
at 4 °C. The cell pellet was suspended in 15 mL cold TFB1 an 
incubated for 90 minutes on ice. Afterwards it was centri-
fuged a second time, the cells were suspended in 4 mL cold 
TFB2 and stored at -80 °C as 50 µL aliquots. 
2.2.4.5 Heat shock transformation of E. coli with Plasmid-
DNA 
Transport of plasmid DNA into E. coli cells was performed by 
heat shock transformation. Therefore, an aliquot of chemi-
cally competent E. coli cells was thawed carefully on ice. 
20 µL of the cells were mixed with 1 µL of purified plasmid 
DNA or with 10 µL reaction mix from ligation. After 20 
minutes storage on ice the cells were incubated at 42 °C for 
45 seconds and afterwards for 2 minutes on ice. 100 µL of 
pre-warmed SOC medium was added to the cells. The trans-
formed cells were plated directly on an 2xYT-GA agar plate. 
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2.2.4.6 Titration of phage particles 
The concentration of a phage preparation was determined 
by infection of E. coli with different phage dilutions. A cul-
ture of E. coli XL1-blue MRF’ ǁas prepared aŶd cultivated un-
til an OD600 of 0.5 was reached. 10 µL of diluted phage parti-
cles in PBS were added to 50 µL of the E. coli culture and 
incubated for 30 minutes at 37 °C. The culture was plated 
onto a 2xYT-GA agar plate. The plates were incubated over-
night at 37 °C and the particle concentration was calculated 
from the number of grown colonies. 
2.2.5 Cell culture methods 
The following cell culture methods were used in this project. 
2.2.5.1 Cultivation of human embryonic kidney cells (HEK-
cells) 
HEK-cells were cultivated and used for the production of 
rAbs. Therefore, an aliquot of cryo conserved cells was care-
fully thawed in 12 mL of culture medium. The suspension 
was centrifuged with 500 xg for 5 minutes and the cell pellet 
was suspended in 13 mL of fresh culture medium. The cell 
suspension was cultivated in an Erlenmeyer flask at 37 °C, 
with 110 rpm and 5 % CO2 content in the air. The cell con-
centration and vitality of the culture was observed by mixing 
a sample with trypan blue solution and counting of cells in a 
Materials and Methods 
72 
Neubauer chamber. After 2-3 days the cells were passaged 
by inoculation of fresh culture media with cultured cells to a 
concentration of 0.2 x105 cells mL-1. The HEK cell culture was 
maintained for approx. 25 passages and discarded after-
wards. 
2.2.5.2 Transfection of HEK-cells for protein production 
HEK cells were transiently transfected with polyethyl-
enimine (PEI) as transfection reagent. The transfection was 
prepared by suspending of 25 µg of expression vector in 1.25 
mL transfection media and mixing it with 62.5 µL 0.1 % (w/v) 
PEI in 1.25 mL transfection media. For production of anti-
bodies in the Fab format, a mixture of 12.5 µg of heavy chain 
expression vector and 12.5 µg of light chain expression vec-
tor was used. After incubation for 20 minutes at room tem-
perature, the mixture was added to 25 mL culture which has 
been grown to a cell concentration of 1.5*106 cells mL-1. The 
culture was cultivated in an Erlenmeyer flask at 37 °C, with 
110 rpm and 5 % CO2 content in the air and was fed after 48 
hours with 25 mL of feed media. The production was 
stopped 96 hours after feeding and the culture was centri-
fuged for 10 minutes with 1,000 xg at 4 °C. The supernatant 
with the produced antibodies was directly used for purifica-
tion or stored at -20 °C. 
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Transfection for small scale productions was performed by 
mixing 5 µg expression vector DNA in 250 µL transfection 
media with 25 µg PEI in 250 µL transfection media and trans-
ferring to 5 mL culture after incubation. Cultivation was per-
formed as described for normal production and 5 mL of feed 
medium was used for feeding. 
2.2.6 Purification methods 
The following purification methods for glucans and antibod-
ies were used in this project. 
2.2.6.1 Purification of glucans 
The glucans were derived as cell free production superna-
tant stabilized with formic acid and were purified as de-
scribed. 
 
Diafiltration 
The glucans were diafiltrated to remove contaminants of the 
production media and the formic acid. The production su-
pernatants were diluted to 1.0 g L-1 glucan in 100 mL with 
water and were adjusted to pH 7.5 with NaOH. In the next 
step the supernatants were diluted further to 1 L with water 
and were reduced to 200 mL with a cross flow filtration cas-
sette (100,000 Da cut off). The supernatants were refilled to 
1 L with water and again reduced to 200 mL. This procedure 
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was repeated until the conductance of the retentate 
dropped to 0 µS cm-1. The glucan solution was thereafter re-
duced to 100 mL and sterilized. 
 
Proteinase K treatment 
SCH and Scleroglucan (S. rolfsii) were additionally treated 
with proteinase K. The production supernatant was diluted 
to 1.0 g L-1 glucan in 100 mL with water and was adjusted to 
pH 7.5 with NaOH. 2 mL Proteinase K buffer and 1 mL of 
10 % (w/v) sodium dodecyl sulfate were added and the solu-
tion was incubated at 80 °C for 4 hours. After cooling down 
to 40 °C, 10 mg of Proteinase K was solved in the solution 
and incubated for 24 h at 40°C under slight shaking. The pro-
teinase K treatment was stopped by incubation at 80 °C for 
4 hours. The solution was diluted to 1 L with water, cleared 
by centrifugation with 13,000 xg for 1 h at 16 °C and was di-
afiltrated as described above. 
2.2.6.2 Purification of recombinant antibodies 
The produced antibodies were purified with the following 
methods. 
 
Affinity purification via Fc domain recognition by protein A 
Recombinant antibodies produced in the scFv-Fc format 
were purified by affinity purification with protein A. 
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Therefore, an automated protein purification system or a 
manually operated purification system was used.  
The automated system was used for supernatants from the 
normal production in HEK cells. 5 mL of 5x protein A binding 
buffer was added to 45 mL of cell free production superna-
tant. This was filtrated and degassed by vacuum filtration 
with a 0.45 µm filter. In the ProfiŶia™ system the superna-
tant was loaded onto a 1 mL protein A column with a flow 
rate of 1 ml min-1. After washing with 30 mL of protein A 
binding buffer, the antibodies were eluted with 4 mL protein 
A elution buffer. The eluate was instantly transferred to a 
10 mL desalting column in which the protein A elution buffer 
was exchanged against PBS. 
The manually operated system was used for supernatants 
from small scale productions. 9.5 ml of cell free supernatant 
was filled into one well of a 24 deep well vacuum filtration 
plate with 500 µL of protein A purification matrix. After 5 
minutes incubation the supernatant was removed. The 
loaded protein A matrix was washed once with 5 mL PBS and 
additional two times with 2.5 mL PBS. 500 µL of protein A 
elution buffer was added to the matrix and this was incu-
bated for 5 minutes. The buffer with the eluted rAbs was di-
rectly transferred to 220 µL of 1 M Tris. The protein A matrix 
was washed two times with 750 µL elution buffer, which was 
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removed and added to the eluate. Afterwards the buffer of 
the eluate was exchanged against PBS by centrifugation with 
1,000 xg for 2 minutes through desalt spin columns. 
The purified antibodies were stored at -80 °C  
 
Affinity purification via His-tag by complexation with nickel 
ions 
The produced antibodies in the Fab format were purified via 
their His-tag by nickel complexation. Therefore 2 mL chelat-
ing sepharose was loaded with nickel ions by incubation with 
2 mL of 0.1 M NiSO4 for 5 minutes. After removal of the re-
sidual NiSO4 solution by centrifugation for 5 minutes with 
500 xg, the Ni-sepharose was washed two times with 20 ml 
water. The cell free production supernatant was supple-
mented with 0.5 M NaCl and was incubated with the Ni-se-
pharose for 45 minutes with smooth rocking at room tem-
perature. The mixture was transferred to an empty chroma-
tography column and the supernatant was removed by grav-
itation. The loaded Ni-sepharose was washed with 25 mL 
His-tag binding buffer. Elution of the protein was performed 
in two steps by incubation of the loaded Ni-sepharose with 
á 1 mL His-tag elution buffer for 5 minutes. The eluate was 
used directly or after storage overnight at 4 °C for size exclu-
sion chromatography 
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Preparative size exclusion chromatography 
Since the antibody for the x-ray crystallography had to be 
free of agglomerates and to be solved in gel filtration buffer, 
size exclusion chromatography was performed. Therefore, 
an automated chromatography system with fraction collec-
tor was used. The eluate from the His-tag affinity purification 
was loaded onto a Superdex™ 75 HiLoad™ 16/60 column 
with 0.75 mL min-1, gel filtration buffer was used as running 
solution. After 30 mL, the flow through was collected in frac-
tions of 1 mL.  
The fractions with the agglomerate free Fab were pooled 
and concentrated with a dialyze spin column (30 kD cut off) 
to a concentration of 10 mg mL-1. The protein solution was 
kept on ice and was used directly for the crystallography ex-
periments. 
2.2.7 Construction of an antibody phage library 
The construction of the antibody phage library from immun-
ized mice was performed as described by L. Toleikis and A. 
Frenzel. [61] Two sub-libraries for antibodies with VL-kappa 
and VL-lambda domain were derived from each mouse. 
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2.2.7.1 Immunization of mice 
Three mice were immunized with SCH-PK by intraperitoneal 
injection. Three injections were applied in two-week inter-
vals. Each injection consisted of 25 µg of SCH-PK and 50 µL 
of the adjuvant Magic™-Mouse (Creative Biomart, New York, 
USA). Four weeks after the third injection, three additional 
injections with 50 µg of SCH-PK and 100 µL of PBS were ap-
plied over a period of three days to boost the B cell prolifer-
ation. Two days later, the mice were sacrificed. Their spleens 
were isolated and homogenized in TRIzol® LS Reagent. 
 
Ethics statement 
The experimental protocols were carried out in accordance 
with the Directive 2010/63/EU of the European Parliament 
and the Council of the European Union of 22 September 
2010 and all procedures were approved by guidelines from 
the Animal Committee on Ethics in the Care and Use of La-
boratory Animals of TU Braunschweig, Germany (Az §5 
(02.05) TschB TU BS Az:33.42502-14-005/08). 
2.2.7.2 RNA isolation and cDNA synthesis 
From the spleen homogenate of each mouse a volume equal 
to 1 x107 of homogenized leucocytes was used to isolate the 
total RNA with the Directzol™ MiniPrep kit. The RNA was 
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solubilized in water and directly used for cDNA synthesis 
with SuperScript™ IV cDNA synthesis kit. The cDNA synthesis 
was performed with the enclosed random hexamer primer 
according the kits instructions. 
2.2.7.3 Cloning of VL and VH into pHAL30 
The cDNA preparation was used for the isolation of the VH 
and VL domain sequences. Therefore, PCR experiments with 
primer sets that are designed to frame VH, VL-kappa and VL-
lambda sequences were performed. 
 
Table 2-21 Primer sets for VH, VL-kappa and VL-lambda se-
quence isolation 
Primer set Forward primer Reverse primers 
   
VH MHC.F 
MHV.B1, MHV.B2, MHV.B3, 
MHV.B4, MHV.B5, MHV.B6, 
MHV.B7, MHV.B8, MHV.B9,  
MHV.B10, MHV.B12 
VL-kappa MKC.F 
MKV.B1, MKV.B2, MKV.B3, 
MKV.B4, MKV.B5, MKV.B6, 
MKV.B7, MKV.B8, MKV.B9, 
MKV.B10 
VL-lambda MLC.F MLV.B 
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Table 2-22 PCR mix for VH, VL-kappa and VL-lambda sequence 
isolation 
Stock solution 
Volumes [µL] per 
50 µL reaction mix 
  
cDNA 1.44 
5x Green GoTag® Reaction Buffer 10.0 
25 mM MgCl2 3.0 
10 mM dNTP mix 1.0 
10 mM forward primer 2.0 
10 mM reverse primer 2.0 
5 U µL-1 GoTag® DNA Polymerase 0.25 
water 30.31 
 
Table 2-23 Temperature profile for VH, VL-kappa and VL-
lambda sequence isolation 
Step Profile Repeats 
   
1. Initial denaturation 95 °C for 2 minutes x1 
2. Denaturation 95 °C for 45 seconds 
 x30 3. Annealing 56 °C for 45 seconds 
4. Elongation 72 °C for 1.5 minutes 
5. Final Elongation 72° C for 5 minutes x1 
6. Store 16 °C forever  
 
The desired PCR products had a size of around 380 bp. They 
were isolated by agarose gel electrophoresis followed by a 
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gel extraction. The products for isolation of VH and VL-kappa 
were each pooled. 
The isolated sequences were equipped with endonuclease 
cleavage sites for cloning by additional PCR experiments. 
The respective primers were used for each product of the 
previous PCR experiments. 
 
Table 2-24 Primer sets for addition of endonuclease sites to 
VH, VL-kappa and VL-lambda sequences 
Primer set 
Forward  
primer 
Reverse primers 
   
VH-Nco/Hind MHC.F.Hind 
MHV.B1.Nco, MHV.B2.Nco, 
MHV.B3.Nco, MHV.B4.Nco, 
MHV.B5.Nco, MHV.B6.Nco, 
MHV.B7.Nco, MHV.B8.Nco, 
MHV.B9.Nco, MHV.B10.Nco, 
MHV.B12.Nco 
VL-kappa-Mlu/Not MKC.F.Not 
MKV.B1.Mlu, MKV.B2.Mlu, 
MKV.B3.Mlu, MKV.B4.Mlu, 
MKV.B5.Mlu, MKV.B6.Mlu, 
MKV.B7.Mlu, MKV.B8.Mlu, 
MKV.B9.Mlu, MKV.B10.Mlu 
VL-lambda-Mlu/Not MLC.F.Not MLV.B.Mlu 
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Table 2-25 PCR mix for addition of endonuclease sites to VH, 
VL-kappa and VL-lambda sequences 
Stock solution 
Volumes [µL] per 
100 µL reaction mix 
  
90 ng µL-1 PCR product 1.0 
5x Green GoTag® Reaction Buffer 10.0 
25 mM MgCl2 6.0 
10 mM dNTP mix 2.0 
10 mM forward primer 2.0 
10 mM reverse primer 2.0 
5 U µL-1 GoTag® DNA Polymerase 0.5 
water 76.5 
 
 
Table 2-26 Temperature profile for addition of endonuclease 
sites to VH, VL-kappa and VL-lambda sequences 
Step Profile Repeats 
   
1. Initial denaturation 95 °C for 2 minutes x1 
2. Denaturation 95 °C for 45 seconds 
x20 3. Annealing 56 °C for 45 seconds 
4. Elongation 72 °C for 1.5 minutes 
5. Final Elongation 72° C for 5 minutes x1 
6. Store 16 °C forever  
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The expected size of the product was 400 bp and was iso-
lated by agarose gel electrophoresis. After gel extraction, 
the products of VH and VL-kappa were pooled each. 
The VH and VL sequences were subsequently cloned into the 
vector pHAL30. First the VL-kappa and VL-lambda sequences 
were cloned into the vector separately. Therefore, each VL 
preparation and the vector pHAL30 were treated with the 
endonucleases NotI and MluI. The linearized vector was ad-
ditionally dephosphorylated with CIP. After heat inactivation 
of the endonucleases, the inserts and the vector were puri-
fied with a PCR clean up kit and used for ligation. 300 ng of 
each insert preparation was ligated with 1 µg of linearized 
vector pHAL30. The ligated products were purified with cen-
trifugal dialyzes tubes (30 kDa cut off) by centrifugation for 
20 minutes with 14,000 xg and refilling with water for three 
times. Afterwards the ligation mixtures were concentrated 
to 60 µL. 20 µL of one ligation were mixed with 12.5 µL of 
freshly thawed electro competent E. coli cells (E. cloni® 10G 
Supreme) and 12.5 µL cold water, incubated on ice for 1 mi-
nute and transferred into a cold electroporation cuvette. 
The DNA was transformed into the cells with an electrical 
pulse of 1.7 kV and 1 mL of warm recovery medium was 
added. The cell suspensions were incubated for 1 hour at 
37 °C in a thermomixer with 600 rpm before they were 
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plated onto a 2xYT-GA agar plate. After overnight incubation 
at 37 °C, single colonies of each transformation were 
checked for correct insert size by colony PCR. The cells from 
each plate were suspended in 25 mL 2xYT medium and the 
plasmid DNA was prepared from those. 
With a second cloning step the VH sequences were added to 
the vectors containing the VL sequences. 7.5 µg of the VH 
preparation, 10 µg of pHAL30 with VL-kappa and of pHAL30 
with VL-lambda were treated with the endonuclease NcoI. 
The preparations were purified with a PCR clean up kit and 
were additionally treated with the second endonuclease 
HindIII. The linearized vector preparations were 
dephosphorylated with CIP. After purification, 1 µg of each 
vector preparation was ligated with 300 ng of the VH prepa-
ration. The ligations were purified with a centrifugal dialyzes 
tube as described in the first cloning step. 20 µL of one liga-
tion were mixed with 25 µL of freshly thawed electro com-
petent E. coli cells (ER2738), incubated for 1 minute on ice 
and transformed into the cells with a 1.7 kV pulse. The cell 
suspension was incubated for 1 hour at 37 °C with 600 rpm, 
plated onto a 2xYT-GA agar plate and incubated overnight at 
37 °C. Single colonies of each transformation were checked 
for correct insert size by colony PCR. The cells from each 
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plate were suspended in 25 mL 2xYT medium and cryo con-
served in 1 mL aliquots. 
2.2.7.4 Packing of library into scFv phage particles 
The generated sub-libraries were packed into scFv phage 
particles for the antibody selection. Therefore, one aliquot 
of a sub-library was thawed and used to inoculate 200 mL 
2xYT-GA media. Starting with an OD600 of 0.07, the culture 
was incubated at 37 °C with 250 rpm until the OD600 reached 
0.5. 20 mL of the culture were infected with 2.5 x1011 cfu of 
hyperphage. After 30 minutes incubation at 37 °C without 
shaking and 30 minutes incubation at 37°C with 250 rpm, the 
culture was centrifuged for 10 minutes with 3,220 xg and the 
cell pellet was resuspended in 400 mL of 2xYT-KA media. The 
scFv phage particles were produced during overnight incu-
bation of the culture at 30 °C with 250 rpm. For purification 
of the scFv-phage, the culture was centrifuged for 
30 minutes with 10,000 xg at 4 °C. 100 mL of phage precipi-
tation solution was added to 350 mL of the supernatant and 
stored overnight at 4°C. The precipitated phage particles 
were isolated by centrifugation (1 h, 10,000 xg, 4 °C) and re-
suspended in 20 mL of phage dilution buffer. This solution 
was filtered with a 0.45 µm sterile filter and mixed with 5 mL 
of phage precipitation solution for a second overnight 
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precipitation at 4 °C. The precipitate was resuspended in 
2 mL of phage dilution buffer after centrifugation (30 min, 
20,000 xg, 4°C). The phage particle titer was determined and 
the scFv phage were stored at 4 °C. 
2.2.8 Selection of glucan binding antibodies (Panning) 
Recombinant antibodies against SCH were selected by am-
plification of scFv phage particle that were isolated through 
binding to immobilized SCH. As source for the antibodies the 
naive human antibody library with the sub-libraries HAL9 
and HAL10 (kindly provided from Prof. Dr. Stefan Dübel & 
Prof. Dr. Michael Hust, Department of Biotechnology, Tech-
nische Universität Braunschweig, Braunschweig, Germany), 
as well as generated immune library with its pooled sub-li-
braries for VL-kappa and VL-lambda were used. 
Each round of selection 8 SCH-PK loaded wells and 8 blank 
wells of a Carbo-BIND™ plate were blocked with 300 µL 
MPBST for 1 hour. 3 x1010 cfu of each sub-library was sus-
pended in 200 µL MPBST and added to two of the blank wells 
(100 µL per well). After 1 hour at room temperature, the su-
pernatants were transferred to the SCH-PK loaded wells and 
were incubated for an additional hour. In the first round of 
selection the SCH-PK loaded wells with the bound phage par-
ticles were washed 10 times with 300 µL PBST. The bound 
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scFv phage particles were eluted by incubation with 200 µL 
10 mg mL-1 trypsin (in PBS) for 30 min at 37 °C. The eluted 
phage of one sub-library were used to infect 10 mL culture 
of E. coli XLϭ Blue MRF’ iŶ ϮǆYT-T media which was grown to 
an OD600 of 0.5. After 30 minutes incubation at 37 °C and 30 
minutes incubation at 37 °C with 250 rpm, the cells were 
separated (2500 xg, 10 minutes, 25°C) and plated on a 2xYT-
GA agar plate. The plates were incubated overnight at 37 °C. 
The grown colonies were suspended in 5 mL 2xYT media and 
used to inoculate 20 mL 2xYT-GA media with an OD600 = 0.01. 
For the production of new scFv phage particles 5 mL of this 
culture was infected with M13K07 helper phage after it 
reached an OD600 = 0.5. During infection the culture was in-
cubated 30 minutes at 37 °C followed by 30 minutes at 37 °C 
with 250 rpm. The infected cells were separated by centrif-
ugation (2,500 xg, 10 minutes, 25 °C), suspended in 5 mL 
2xYT-AK media and cultivated overnight at 30 °C with 
500 rpm in a 24 deep well plate. The culture was centrifuged 
with 3,220 xg for 20 min at 4 °C and 100 µL of the superna-
tant with the produced antibody phage particles was used 
for an additional round of selection. Three rounds of selec-
tion were done. In the second round 20 washing steps and 
in the third round 30 washing steps were carried out after 
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10 µL of the eluted phage in the third round were used to 
prepare different dilutions in PBS, 50 µL of E. coli XL1 Blue 
MRF’ cells (OD600 of 0.5) were infected with 10 µL of diluted 
phage and plated on 2xYT-GA agar plates. The plates were 
incubated at 37°C and 92 grown colonies were transferred 
to 130 µL 2xYT-GA each in a polypropylene multiwell plate 
(u-shape bottom) and cultivated for 6 hours at 37 °C with 
800 rpm. 60 µL 80 % (v/v) sterile glycerol was added to the 
cultures and the plate was stored as master plate at -80 °C. 
An antigen ELISA with soluble scFv was performed to identify 
the SCH binding antibodies. For production of soluble scFv, 
a micro well plate was filled with 150 µL 2x YT-GA and inoc-
ulated with 1 µL form the 92 isolated E. coli clones stored in 
the master plate. 2 of the 4 residual wells were inoculated 
with an E. coli clone which contains the information for an 
anti-lysozyme scFv as positive control and the other 2 wells 
were used as negative control (no inoculation). After 2 hours 
incubation at 37 °C and 800 rpm, the plate was centrifuged 
(2,000 xg, 10 minutes, 30 °C). The media was exchanged for 
2xYT-AI and the plate was incubated at 30°C and 800 rpm 
overnight. A Carbo-BIND™ plate was loaded with SCZ-PK be-
sides 2 wells which were coated with lysozyme (100 µL well-
1, 0.5 µg mL-1 lysozyme in PBS). As additional control for un-
specific antibodies a second Carbo-BIND™ plate was coated 
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with BSA (100 µL well-1, 0.5 µg mL-1 BSA in PBS). The loaded 
plates were blocked with MPBST (300 µL well-1) and washed 
three times with PBST (300 µL per well). 50 µL of MPBST 
were added to the wells of the scFv production plate, which 
was thereafter centrifuged with the 3220 xg for 20 min at 4 
°C. 100 µL of the supernatants were transferred to the 
Carbo-BIND™ plate and to the control plate. The plates were 
incubated for 1 hour at room temperature and washed 3 
times with PBST, filled with 100 µL well-1 of monoclonal anti-
c-myc tag mouse antibody 9E10 (1:50 in MPBST) and incu-
bated for 1 hour again. The plates were washed 3 times with 
PBST and incubated for 1 h with the 100 µL well-1 peroxidase-
conjugated goat anti-murine Fc antibody A0168 (1:10,000 
MPBST). For the visualization of the ELISA the washed wells 
of the plates were filled with 100 µL freshly mixed TMB (20 
vol. TMB A and 1 volume TMB B). The color reaction was 
stopped after 10-15 minutes development by adding 100 µL 
0.5 M H2SO4. The absorbance was measured at 450 nm (ref-
erence wavelength: 620 nm). The E. coli clones which hold a 
positive tested rAb were used for inoculation of overnight 
cultures (2xYT-GA, 37 °C, 250 rpm). Plasmid preparations 
were derived from each culture and were sequenced. 
 
Results 
90 
3 Results 
3.1 Construction of an immune library 
The antibody generation was planned to be performed by 
selection from phage displayed libraries of recombinant an-
tibodies. Therefore, an immune library was constructed 
from three mice which had been immunized with SCH-PK. 
The immunization experiments were kindly performed by 
Sabine Buchmeier (Institute for Physical and Theoretical 
Chemistry, Technische Universität Braunschweig, Braun-
schweig, Germany). For immunization three injections of 
SCH-PK were applied in two-week intervals. Four weeks after 
the third injection, three additional injections were applied 
over a period of three days to boost the B cell proliferation. 
Two days later, the mice were sacrificed and total RNA was 
derived from their spleens. After reverse transcription to 
cDNA, the sequences of VH and VL domains were isolated by 
PCR with sets of respective primers. Subsequently, the VH 
and VL sequences were cloned into the library vector 
pHAL30. The sub-libraries (mouse 1 lambda, mouse 1 kappa, 
mouse 2 lambda, etc.) were packed into antibody phage par-
ticles with the helper phage hyperphage or M13K07. The 
analysis for the number of vectors with successful insertion 
Results 
91 
of VH and VL showed insert rates of 69 % in the sub libraries 
mouse 1 lambda and mouse 1 kappa, 63 % in mouse 2 
kappa, mouse 3 lambda and mouse 3 kappa and 31 % in 
mouse 2 lambda (Table 3-1). The titers of the hyperphage 
packed sub-libraries ranged from 0.9 x1012 cfu mL-1 to 
1.7 x1012 cfu mL-1 and for the M13K07 packed sub-libraries 
from 0.8 x1013 cfu mL-1 to 2.5 x1013 cfu mL-1. Presentation of 
scFv-p3 fusions in the packed sub-library preparations were 
checked via immunoblot by using the antibody 9E10 which 
is directed against the myc-tag in the peptide linker between 
scFv and p3. The blot showed stained bands at an apparent  
 
Table 3-1 Generated immune library with insertion rates and 
titers of the antibody phage packed sub-libraries 
Mouse 
Light  
chain  
class 
Insertion 
rate 
Titer hyper- 
phage packed  
sub-library 
Titer M13K07 
packed  
sub-library 
     
1 
 lambda 69 % 0.9 x1012 cfu mL-1 1.1 x1013 cfu mL-1 
 kappa 69 % 1.4 x1012 cfu mL-1 2.3 x1013 cfu mL-1 
     
2 
 lambda 31 % 1.7 x1012 cfu mL-1 1.2 x1013 cfu mL-1 
 kappa 63 % 1.0 x1012 cfu mL-1 2.5 x1013 cfu mL-1 
6     
3 
 lambda 63 % 1.7 x1012 cfu mL-1 1.4 x1013 cfu mL-1 
 kappa 63 % 1.0 x1012 cfu mL-1 0.8 x1013 cfu mL-1 
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molecular weight of ~70 kDa. This band was observed also in 
the positive control (naive library HAL10) and correlates with 
the suŵ of the ŵoleĐular ǁeights of sĐFǀ ;≈Ϯϱ-30 kDa) and 
p3 (43.2 kDa). The hyperphage packed sub-libraries as well 
as the M13K07 packed sub-libraries were each pooled for 
lambda-VL and kappa-VL. 
 
3.2 Establishment of an immobilization method for 
Schizophyllan 
Before selection of recombinant antibodies from the anti-
body libraries, an immobilization method for SCH had to be 
established. Freund showed that immobilization of β-D-glu-
can via adsorption onto common multiwell plate materials is 
not stable which leads to a loss of antigen during selection 
and consequently to a loss of potential SCH binding antibod-
ies [62]. Therefore, three methods for immobilization of pol-
ysaccharides via covalent binding were compared. The first 
method was immobilization onto magnetic beads which 
were functionalized with hydroxyl-groups, the second 
method was immobilization onto magnetic beads which 
were functionalized with hydrazide-groups, and the third 
method was immobilization onto Carbo-BIND™ multiwell 
plates (Corning, New York, USA) which were functionalized 
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with hydrazide-groups [59, 60]. Analyses was performed 
qualitatively with the ß-D-Glucan sensitive Glucatell® kit.  
22.5 ng SCH-PK were used to coat 31.5 µg Beads and one 
cavity of a Carbo-BIND plate (50 µL well-1). After 10 times 
washing with 100 µL glucan-free water (component of the 
kit), 25 µL glucan-free water was added to each. All methods 
showed a positive result for SCH immobilization (Figure 3-1). 
 
 
Figure 3-1 Analysis of immobilization methods for SCH via 
Glucatell® kit. Here, the result of SCH immobilization onto hy-
droxyl-functionalized magnetic beads, hydrazide-functional-
ized magnetic beads and a Carbo-BIND multiwell plate is 
shown. After coating and removal of unbound glucan the car-
rier matrices were checked for bound SCH with Glucatell® kit 
(blue) and compared with matrices which were analogous 
treated with water (yellow). Analysis was performed in du-
plets. 
Results 
94 
Due to minor experimental effort the SCH binding onto 
Carbo-BIND multiwell plates was chosen as immobilization 
method for antibody selection. 
3.3 Generation of anti-Schizophyllan antibodies 
Anti-Schizophyllan antibodies were selected from the phage 
displayed libraries by panning for binding of immobilized 
SCH-PK. Three rounds of panning were performed with each 
of the pooled libraries and additionally with the human 
based naive antibody libraries HAL9 and HAL10 (kindly pro-
vided from Prof. Dr. Stefan Dübel & Prof. Dr. Michael Hust, 
Department of Biotechnology, Technische UniversitätBraun-
schweig, Braunschweig, Germany). Single clones were iso-
lated and tested for unspecific binding to BSA by antigen 
ELISA (Figure 3-2). Overall 205 of 644 isolated clones where 
tested positive for SCH-PK binding and for sufficient specific-
ity (signal ratio BSA:SCH-PK < 5 %). No positive clone was iso-
lated from the panning with the naive library HAL10.  
Randomly, 35 of the clones which showed reproducible 
specificity and production as soluble scFv were chosen for 
sequence analysis. The sequences were compared with the 
respective germline sequences via the online sequence anal-
ysis tools IMGT/V-QUEST from the International ImMunoGe-
neTics information system® (IMGT®, http://www.imgt.org) 
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and VBASE2 (http://www.vbase2.org) [63–65]. Analysis of 
the sequences identified 15 individual rAbs, 4 rAbs of the 
mouse immune library and 11 rAbs of the human naive li-
brary.  
All 4 rAbs of the immune library contain VH domains of the 
subfamily VH1 and VL-domains of the kappa sub family VK4. 
Noticeable, three rAbs were selected from the lambda VL 
pool despite having VL domains of the kappa type which 
could be explained by cross contamination of the pools. The 
11 rAbs from the naive library contain mainly VH domains of 
gene subfamily VH1 except for JoJ58C5 which has a VH do-
main of gene subfamily VH5. Their VL domains are all of the 
lambda type and show different gene subfamilies: VL1 
(mainly), VL2 (JoJ58B9), VL3 (JoJ58B10 & JoJ61G1) and VL6 
(JoJ58C10). A detailed overview of the gene combinations 
for the VH (V, D and J genes) and for the VL domain (V and J 
genes) of each rAb is listed in Table 3-2. 
For further analysis, the 15 rAbs were converted into the 
scFv-Fc format consisting of the scFv fused to a murine IgG2c 
Fc part. The scFv-Fc format is a bivalent antibody compara-
ble to a full-length IgG. Therefore, the scFv sequence of each 
rAb was cloned into the expression vector pCSE2.6-mIgG2c- 
Fc-XP and transiently transfected into HEK293-6E cells. 
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Figure 3-2 Antigen ELISA for identification of SCH specific an-
tibodies. This example shows the result for isolated clones in 
master plate JoJ48. The production supernatants of the se-
lected clones were transferred into Carbo-BIND™ plates which 
were coated with SCH-PK (blue) and BSA (yellow). As positive 
control supernatant containing scFv of the antibody D1.3 
(anti–Lysozyme) were used for the cavities H11 and H12 
(coated with lysozyme, green) of each plate. ScFv-free culture 
media was used as negative control in the cavities H9 and H10 
(violet). 
 
5 days after transfection, the secreted scFv-Fc were purified 
from the cultivation supernatant by protein A affinity chro-
matography and transferred into PBS. The purity of the scFv-
Fc was analyzed by SDS-PAGE and coomassie staining. A 
scFv-Fc consists of a homodimer with a molecular weight of 
approx. 110 kDa and is stabilized by disulfide bonds under 
reducing conditions it dissociates into two monomers of ap-
prox. 55 kDa. In the SDS-PAGE each of the produced scFv-Fc 
showed bands for the expected molecular weight of about 
55 kDa. 
3.4 Binding specificity of the generated antibodies 
The first analyzed characteristic was the binding strength of 
each rAb in form of the half maximal effective concentration 
(EC50). Therefore, serial dilutions (approx. 0.95 pM - approx. 
950 nM) of the rAb were applied on SCH-PK loaded and 
blank Carbo-BIND™ multiwell plates and were analyzed by 
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titration ELISA. The absorbance signal on the SCH-PK loaded 
plates showed a sigmoidal increase of the absorbance signal 
with increasing scFv-Fc concentration in a half-logarithm 
plot (Figure 3-3). The EC50 values were derived from the re-
gression of absorbance signal against the logarithm of anti-
body concentration by a sigmoidal function (3 parameters). 
JoJ48C11 showed the highest binding strength with an EC50 
value of 0.16 nM. The EC50 values of the other rAb ranged 
from 0.19 nM to 6.6 nM (Table 3-3). 
 
 
 
Figure 3-3 Titration ELISA of the rAb for EC50 calculation. This 
example shows the half logarithmic plotted absorbance signals 
from the titration ELISA of JoJ48C11, JoJ58B9 & JoJ60A11. Se-
rial dilutions ranging from approx. 0.95 pM to approx. 95 nM 
of each rAb in the scFv-Fc format were applied on SCH-PK 
loaded and blank Carbo-BIND™ ŵultiǁell plates. Analysis was 
performed in triplets. 
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Table 3-3 Estimated EC50 values for the scFv-Fc of the derived 
rAb 
 rAb EC50 [nM] rAb EC50 [nM] 
    
JoJ48C11 0.16 ± 0.005 JoJ58C10 0.19 ± 0.02 
JoJ48D6 1.33 ± 0.30 JoJ58E9 1.25 ± 0.51 
JoJ48F1 0.21 ± 0.007 JoJ58G2 3.55 ± 1.11 
JoJ49D10 0.19 ± 0.01 JoJ60A11 1.91 ± 0.24 
JoJ58A2 6.61 ± 2.59 JoJ60E9 0.99 ± 0.15 
JoJ58B9 0.19 ± 0.003 JoJ60E12 0.37 ± 0.01 
JoJ58B10 0.63 ± 0.03 JoJ61G1 0.87 ± 0.03 
JoJ58C5 0.28 ± 0.001   
 
The next analyzed characteristic was the antigen specificity 
of the rAb. It was analyzed in a competitive approach with 
different saccharides and yeast extract as competitors. Each 
rAb was used in a concentration that showed 40 % of the 
saturation signal in the titration ELISA and was incubated 
with different concentrations of competitor. After incuba 
ion the mixtures were applied on SCH-PK loaded Carbo-
BIND™ ŵultiǁell plates and the amount of unbound rAb was 
analyzed. Thus, with increasing concentration of a competi-
tor which is interacting with the rAb, the absorbance signal 
should decrease. 
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A first experiment (Figure 3-4) was performed with SCH-PK 
as competing substance in concentrations from 0.32 µg mL-1 
to 316 µg mL-1. JoJ48C11, JoJ48D6, JoJ48F1, JoJ49D10 and 
JoJ58B9 were the only rAbs which showed the expected de-
crease of absorbance signal in this experiment. 
 
  
Figure 3-4 Competitive ELISA of rAb with SCH-PK as competi-
tor. This example shows the half logarithmic plotted absorb-
ance signals from the competitive ELISA with JoJ48C11, 
JoJ58B9 & JoJ60A11 (all as scFv-Fc). Serial dilutions ranging 
from 0.32 µg mL-1 to 316 µg mL-1 of SCH-PK were incubated 
with each rAb in the scFv-Fc format before application on SCH-
PK loaded Carbo-BIND™ ŵultiǁell plates. The rAbs were also 
incubated without competitor as negative control and mark of 
maximal signal. Analysis was performed in triplets. 
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The experiment was repeated with more competitors in a 
concentration range from 3.12 ng mL-1 to 1 mg mL-1 (Figure 
3-5). 
 
 
Figure 3-5 Competitive ELISA of antibody JoJ48C11 for the 
characterisation of antigen specificity. JoJ49D10 (scFv-Fc) was 
preincubated in dilutions of different carbohydrates or yeast 
extract ranging from 3.12 ng mL-1 to 1 mg mL-1 before being 
added to SCH-PK loaded Carbo-BIND™ ŵultiǁell plates. The 
absorbance signals were normalized by division with the ab-
sorbance of respective samples without competitor. Analysis 
was performed in triplets. 
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In this experiment only the rAbs JoJ48C11, JoJ48F1, 
JoJ49D10 and JoJ58B9 were analyzed. The other rAbs except 
for JoJ48D6 were dismissed due to the lack of interaction 
with SCH-PK in its solved form. JoJ48D6 was not further an-
alyzed since it is scarcely producible while showing low bind-
ing strength. 
The following substances were used as competitors: SCH-PK, 
SCH, scleroglucan (S. rolfsii), scleroglucan (S. rolfsii) treated 
with proteinase K, Cinerean, Fructigan, Scleroglucan of 
S. glucanicum, SCH from Contipro Biotech, Actigum™ CS 11 
(scleroglucan), Laminarin, Dextran, Xanthan, Laminarihex-
aose, β-(1,6)-D-gentiobiose, yeast extract (Ohly, Hamburg, 
Germany) and glucose. Furthermore, NaOH treated SCH-PK 
was used, due to its changed secondary structure (triplex de-
natured to single chains, partial formation of cyclic struc-
tures). It was derived by adding NaOH until a pH of 13.8 had 
been reached and was neutralized with HCl before use. So-
lutions of degraded SCH-PK and SCH were also used. Both 
were prepared by overnight incubation of SCH-PK and SCH 
with endoglucanase from Penicillium funicolosum (kindly 
provided by Erbslöh, Geisenheim, Germany) at 50 °C. The 
endoglucanase was inactivated by heating up to 80 °C for 
20 minutes. 
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The fuŶgal β-(1,6)-ďraŶĐhed β-(1,3)-D-glucan preparations 
of SCH, Scleroglucan, Cinerean and Fructigan exhibited clear 
interactions with each of the four antibodies. In contrast, an 
interaction for the non-fungal glucans Xanthan and Dextran 
as well as for degraded (glucanase treated) SCH, the linear 
heǆaŵer of β-(1,3)-linked D-glucose Laminarihexaose, the 
diŵer of β-(1,6)-linked D-glucose gentiobiose, monomeric D-
glucose could not be observed. This hinting towards the 
reĐogŶitioŶ of iŶtaĐt β-(1,6)-branched β-(1,3)-D-glucan mol-
ecules. The media component yeast extract did not interact 
as well, excluding the recognition of possible non-glucan. In-
terestingly, NaOH treated SCH-PK just slightly interacted 
with all four rAbs but it was not quantitative determinable. 
Additionally, Laminarin seemed to be slightly bound by 
JoJ48D10. 1 mg mL-1 Xanthan showed also influence in bind-
ing for JoJ48C11 and JoJ48F1 at the highest concentration. 
But this interaction was most likely based on to the high vis-
cosity of the Xanthan solution. 
The interaction strengths of the strong competitors were de-
termined as EC50 value similar as described for the binding 
strength of the antibodies (Table 3-4). Scleroglucan of S. glu-
canicum showed the highest interaction strength for the 
rAbs JoJ48C11, JoJ48F1 and JoJ49D10 with EC50 values of 
3.1 µg mL-1, 1.7 µg mL-1 and 4 µg mL-1. The highest inter-
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action with JoJ58B9 was observed for SCH-PK with an EC50 
value of 1.7 µg mL-1. 
 
Table 3-4 EC50 values of competitors which are recognized 
by the recombinant antibodies 
Competitors 
EC50 values [µg mL-1] 
JoJ48C11 JoJ48F1 JoJ49D10 JoJ58B9 
     
SCH-PK 25.1 ± 1.8 24.9 ± 3.7 7.8 ± 1.0 1.5 ± 0.4 
SCH 36.2 ± 4.6 29.4 ± 6.4 9.1 ± 0.6 3.9 ± 0.5 
Scleroglucan-PK 
(S. rolfsii) 
54.4 ± 2.0 52.3 ± 5.3 19.9 ± 2.8 6.9 ± 1.2 
Scleroglucan 
(S. rolfsii) 
83.1 ± 5.1 54.5 ± 13.2 34.0 ± 1.2 2.6 ± 0.3 
Cinerean 4.2 ± 0.2 4.7 ± 0.7 0.5 ± 0.1 6.7 ± 0.9 
Fructigan 6.8 ± 0.4 8.8 ± 1.8 1.0 ± 0.2 6.1 ± 0.3 
Scleroglucan  
(S. glucanicum) 
3.1 ± 0.2 1.7 ± 0.5 0.4 ± 0.1 1.9 ± 0.6 
SCH (Contipro 
 biotech) 
8.2 ± 1.2 7.0 ± 1.2 1.1 ± 0.2 2.0 ± 0.3 
Actigum CS11 
(Scleroglucan) 
88.5 ± 5.0 74.2 ± 14.4 31.7 ± 1.5 2.3 ± 0.1 
 
The results indicate the specificity of the rAb for the polysac-
charide structure of SCH and for other fungal β-(1,6)-
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branched β-(1,3)-D-glucans with similar structure. This spec-
ificity is limited to full length glucans with their native triple 
helical conformation in water. 
3.5 Complex structure model of JoJ48C11 with SCH 
Identification of the binding epitope for the rAb was ap-
proached by structure analysis via X-ray crystallography. The 
analysis was performed with JoJ48C11, since it exhibits the 
highest binding strength and shows high sequence similarity 
with the other two rAb JoJ48F1 and JoJ49D10 from the im-
mune library. For the crystallization experiments JoJ48C11 
was produced in the Fab format. Therefore, its VH and VL 
domain sequence were cloned into the expression vectors 
pCSE2.5-Fab-h-HIS-XP and pCSE2.5-Fab-k-HIS-XP, which 
were co-transfected into HEK293-6E cells for production. 
The produced Fab was isolated via HIS-tag affinity purifica-
tion and ran through size exclusion chromatography to de-
rive a monodisperse protein solution. The purity of the Fab 
was validated by SDS-PAGE with coomassie staining. A Fab 
consists of a heterodimer with a molecular weight of approx. 
50 kDa and is stabilized by a disulfide bond. Under reducing 
conditions, it dissociates into two monomers of approx. 
25 kDa. In the SDS-PAGE the produced Fab showed a band 
for the expected molecular weight of about 25 kDa. After 
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concentration of the solution for the crystallization experi-
ment, the activity of JoJ48C11 in the Fab format was vali-
dated by ELISA (Figure 3-6) by using solutions ranging from 
20.33 µM to 0.64 pM and application onto SCH-PK coated 
Carbo-BIND™ plates. The calculated EC50 value was 123.4 ± 
11.4 nM.  
 
 
Figure 3-6 Titration ELISA of JoJ48C11 in the Fab format. Half 
logarithmic plot of absorbance signals from the titration ELISA 
of JoJ48C11 in the Fab format. Serial dilutions ranging from ap-
prox. 0.6 pM to approx. 20.3 µM of each rAb in the scFv-Fc for-
mat were applied on SCH-PK loaded and blank Carbo-BIND™ 
multiwell plates. Analysis was performed in triplets. 
 
The crystallization and X-ray diffraction experiments as well 
as the structure modelling were performed by Dr. Kwang 
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Hoon Sung (working group ͞StruĐture and Function of Pro-
teiŶs͟, Helmholtz Centre for Infection Research, Braun-
schweig). Protein crystals were grown in 200 nL Fab solution 
and an equal volume of reservoir solution in a 96-well sitting-
drop Intelli-plates (Hampton Research, Aliso Viejo, USA) at 
20 °C. The first crystals were obtained with a precipitant con-
taining 0.1 M Tris (pH 8.5), 0.2 M lithium sulfate and 
30 % (w/v) polyethylene glycol (avg. 4,000 kDa). After wash-
ing with cryoprotectant [0.1 M Tris (pH 8.5), 0.2 M lithium 
sulfate and 30 % (w/v) polyethylene glycol (avg. 4,000 kDa) 
and 20 % (w/v) glycerol] and flash-cooling in liquid nitrogen, 
a single needle of the needle-shaped multicrystals was iso-
lated and a data set with 3 Å resolution was collected. Dif-
fraction data were processed and scaled using autoPROC 
with XDS, pointless and aimless [66–70]. The structure of 
JoJ48C11 was solved (PDB entry 6EV1) with the automated 
molecular replacement pipeline BALBES and the Fab frag-
ment of a chimeric antibody against CD25 (PDB entry 
1MIM7) as search model. An initial atomic model was man-
ually improved using COOT and refined with PHENIX and 
REFMAC by standard protocols [71, 72]. Furthermore, the 
co-crystallization of JoJ48C11 with native SCH and Laminari-
hexaose was pursued. While the generation of a co-crystal 
with SCH failed, it was possible to generate a 2.4 Å data set 
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of JoJ48C11 in complex with Laminarihexaose (PDB entry 
6EV2). Therefore, new crystals were grown with optimized 
precipitant [0.1 M HEPES (pH 7.5), 0.1 M sodium acetate, 
0.2 M lithium sulfate, 25 % (w/v) polyethylene glycol (avg. 
4,000 kDa)] using the existing crystals as macroseed (600 nL 
precipitant and 100 nL macroseed crystal and 500 nL Fab so-
lution). The JoJ48C11-Laminarihexaose complex was derived 
by adding 50 mM Laminarihexaose to the crystal drop and 
incubation for one week with subsequent flash freezing. The 
structure of the complex was solved by molecular replace-
ment with PHASER as included in the PHENIX software suite 
using the apo-structure of JoJ48C11 Fab as search model [73, 
74]. Details about the data collection and refinement statis-
tics can be seen in Table 11-1 (chapter: supplemental infor-
mation). 
The derived structure of JoJ48C11 (Figure 3-7) adopts the ex-
pected dimer of heavy and light chain which both consist of 
two Ig domains (constant and variable domain). The Ig do-
mains show the typical immunoglobulin fold characterized 
by two anti-parallel β-sheets packed against each other [75]. 
With the solved structure of the JoJ48C11-Laminarihexaose 
complex a binding site was identified which is probably in-
volved in binding of SCH (Figure 3-8, A). The 2.4 Å-structure 
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Figure 3-7 Solved overall structure of JoJ48C11 in the Fab for-
mat (PDB entry 6EV1). The model shows the solved structure 
of JoJ48C11, consisting of the variable and the constant do-
mains from the heavy chain (VH in blue and CH1 in grey) and 
the light chain (VL in green and CL in white). The domains show 
the typical immunoglobulin beta barrel structure with three 
loop structures in the variable domains forming the CDRs (light 
blue in VH and light green in VL). 
 
showed that the glucose of the non-reducing end of Lami-
narihexaose is bound to a cavity-like structure at the margin 
of the antigen binding area. The structure is formed by CDR3 
of the heavy chain and CDR2 of the light chain. In the cavity-
like structure, the residue Asp105 in CDR3 of the heavy chain 
(Asp105H) binds the O4- and O6-atoms of the non-reducing 
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end of Laminarihexaose via hydrogen bonds in a bidentate 
fashion. A second possible binding site was found by calcu-
lation of molecular docking models with SwissDock using the 
RU of SCH (CID:24777, PubChem Compound Database) as 
ligand and the results were visualized with the UCSF Chimera 
package [76–79]. 256 models in 44 clusters were generated 
and then inspected to select the most likely models for fur-
ther experimental analysis. Two similar poses were identi-
fied that show docking of the monomeric unit inside of the 
typical antigen binding area by location of the β-(1-6)-linked 
glucose inside of a second cavity structure. (Figure 3-8, B) 
The second cavity is located in the typical area of antigen 
binding and formed by CDR2 and CDR3 of the heavy chain as 
well as CDR3 of the light chain.  
The generation of a model for the complex of JoJ48C11 and 
SCH was performed with the information gained from the X-
ray structure and computational analysis. A model of triple 
helical SCH for the simulation of binding was computed from 
the solved structure of triple helical curdlan as described by 
Kony et al. [8, 80]. A conspicuous characteristic of the anti-
body was the distance of approx. 18 Å between both identi-
fied binding sites which correlates with the minimal distance 
ďetǁeeŶ tǁo β-(1,6)-linked glucose residues of SCH with the 
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Figure 3-8 Identification of possible SCH binding sites in 
JoJ48C11. (A) Cavity structured binding site identified by the 
structure of the JoJ48C11 Fab/Laminarihexaose complex (PDB 
entry 6EV2; carbohydrate in black, VH in blue; VL in green). The 
glucose residue of the reducing end is bound by Asp105H via 
hydrogen bonds (dashed lines) in a bidentate fashion. (B) Cav-
ity-like structured binding side identified by computational 
modeling with monomeric unit of SCH as ligand. The β-(1,6)-
linked glucose is located inside of the cavity. 
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same spatial direction (Figure 3-9, A) [81]. Under assumption 
that the binding site for the reducing end of Laminarihex-
aose normally binds a β-(1,6)-linked glucose of SCH, a bind-
ing model was generated by fitting the SCH model onto the 
antibody structure with positioning β-(1-6)-linked glucose 
residues of SCH chain 1 the identified cavity-shaped binding 
sites. After energy minimization with the YASARA Energy 
Minimization Server, the final model shows that the triple 
helix fits very well into the binding area of the antibody with 
each of the binding sites accommodating a β-(1,6)-linked 
glucose (Figure 3-9, B) [82]. 
The validation of the binding model was performed by bind-
ing studies with point mutants of JoJ48C11. The mutants 
where generated by exchange of codons for specific amino 
acid residues for an alanine codon via quick change PCR. The 
exchanged amino acid residues were the respective ones 
identified by the X-ray structure analysis and computational 
analysis (Trp33H, His35H, Trp47H, Tyr50H, Glu59H, Trp100H, 
Asp105H, Trp90L and Asn93L). Additionally, mutants were 
used with residues exchanged located close to the SCH bind-
ing sites in the binding model (Tyr27H, Ser31H, Tyr57H, 
Asp49L, Lys52L and Ser55H). The mutants were produced as 
scFv-Fc in EXPI293-F cells and were purified via protein A af-
finity purification. Purity of the produced point mutants 
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Figure 3-9 Binding model of JoJ48C11 with SCH. (A) Conform-
ity of the 18 Å distance between two β-(1,6)-linked glucose 
residues of SCH protruding to the same direction and between 
the two identified cavity-shaped binding sites (SCH chain 1 in 
red; SCH chain 2 in black; SCH chain 3 in grey; VH in blue; VL in 
green). (B) The generated structure model of the JoJ48C1-SCH 
complex. 
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were checked by SDS-PAGE with coomassie staining. The in-
fluence of the point mutations on JoJ48C11 was analyzed via 
titration ELISA. Therefore, the mutants were applied on SCH-
PK coated Carbo-BIND™ plates in a concentration range 
from 3 fM to 950 nM (Figure 3-10).  
 
 
Figure 3-10 Titration ELISA with point mutants of JoJ48C11. 
This example shows the half logarithmic plotted absorbance 
signals from the titration ELISA of JoJ48C11 in the scFv-Fc for-
mat and its point mutants Trp33AlaH, Asp105AlaH as well as 
Trp90AlaL. Serial dilutions ranging from 3 fM to 950 nM of each 
mutant were applied on SCH-PK loaded and blank Carbo-
BIND™ ŵultiǁell plates. Analysis was performed in triplets. 
Results 
117 
The calculated EC50 values were compared (Table 3-5). With 
an EC50 value of 0.6 nM (approx. 3 times the value of 
JoJ48C11) and higher, significant decrease of the binding 
strength was observed for the exchange of the nine residues 
Tyr27H, His35H, Trp47H, Trp100H, Asp105H, Asp49L, Lys52L 
and Trp90L. The strongest decrease of binding was observed 
for the exchange of Asp105H with an EC50 value not quanti-
fiable in our experiments (>> 200 nM), showing the im-
portance of this residue. The alanine mutant for Asp49L 
showed the second highest EC50 value of roughly 163.2 nM. 
The values of the alanine mutants for the residues Tyr27H, 
His35H, Trp47H, Trp100H, Lys52L and Trp90L ranged from 
0.9 nM to 10.9 nM and verified the significance of those res-
idues for the binding of SCH as well. 
 
Table 3-5 EC50 values from point mutants of JoJ48C11 
scFv-Fc EC50 [nM]  scFv-Fc EC50 [nM] 
     
JoJ48C11 original 0.22 ± 0.01  Mutant Glu59AlaH 0.52 ± 0.03 
Mutant Trp27AlaH 0.86 ± 0.11  Mutant Trp100AlaH 10.94 ± 1.15 
Mutant Ser31AlaH 0.22 ± 0.04  Mutant Asp105AlaH >> 1000 
Mutant Trp33AlaH 0.36 ± 0.08  Mutant Asp49AlaL 163.2 ± 9.5 
Mutant His35AlaH 2.28 ± 0.17  Mutant Lys52AlaL 4.78 ± 0.26 
Mutant Trp47AlaH 6.40 ± 1.17  Mutant Ser55AlaL 0.30 ± 0.06 
Mutant Tyr50AlaH 0.30 ± 0.05  Mutant Trp90AlaL 1.07 ± 0.09 
Mutant Tyr57AlaH 0.22 ± 0.02  Mutant Asn93AlaL 0.23 ± 0.02 
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The significant role of Asp105H, that was identified by the 
JoJ48C11 Fab Laminarihexaose complex was verified. The 
decrease of binding strength observed by exchange of  
 
 
Figure 3-11 Paratope of the rAb JoJ48C11. A view from above 
on the antibody paratope. The amino acid residues, which 
showed influence in binding of SCH are displayed and named 
(VH in blue; VL in green). Additionally, the two β-(1,6)-linked 
glucose moieties of SCH chain 1 (red); the β-(1,6)-linked glu-
cose moiety and β-(1,3)-linked glucose moiety of SCH chain 2 
(black) and the β-(1,3)-linked glucose moiety of SCH chain 3 
(grey) which are possibly involved in the interaction are plot-
ted. 
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His35H, Trp47H, Trp100H and Trp90L validated the second 
cavity structure identified by computational docking with 
the RU of SCH. Trp27H, Asp49L and Lys52L are located be-
tween both cavity-shaped binding sites and showed further 
points of interaction with the triple helical SCH. 
Next to the two β-(1,6)-linked glucose moieties of SCH chain 
1 which fit into the cavity-shaped binding sites, the complex 
model suggests additional interacting glucose moieties of 
the SCH triplex. One β-(1,6)-linked glucose moiety and one 
β-(1,3)-linked glucose moiety of SCH chain 2 interact with VH 
and VL in the area between the two binding cavities, and one 
β-(1-3)-linked moiety of SCH chain 3 interacts with VL near 
the second cavity-shaped binding site (Figure 3-11). 
4 Discussion 
The first part of this study involved the construction of an 
immune library and the antibody generation. The immune 
library originated from three mice which were immunized 
with proteinase K treated Schizophyllan (SCH-PK). SCH-PK 
was applied to avoid maturation of IgG antibodies against 
possible protein contaminants associated with SCH. From 
the mice, the genetic information of the IgG VL domains and 
VH domains were isolated and subsequently cloned into the 
library vector pHAL30. Two sub-libraries containing VL 
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domains of the kappa or lambda type, were generated for 
each mouse. Nearly all sub-libraries showed over 60 % inser-
tion content of complete VH and VL pairs, except for the VL 
lambda sub-library of mouse 2 with 30 % insertion content. 
Due to the boosted expansion of the respective B-lympho-
cytes before the sacrifice of the mice, the mRNA of anti-SCH 
IgG in the isolated mouse spleens should have been preva-
lent. Therefore, the generated libraries are assumed to con-
tain predominantly phagemids with inserts of anti-SCH IgG 
even at a low insertion content like 30 %. Consequently, the 
insertion contents were accepted and not further improved. 
Immune libraries represent the IgG VL domain and VH do-
main variants of the donor after immunization with the an-
tigen of interest. Those libraries show a higher potential to 
generate antibodies with high affinity for a specific antigen 
since they are based on IgG antibodies which have been ma-
tured in vivo for binding to the antigen of interest [83]. 
Next to the immune library the naive libraries HAL9 and 
HAL10 were used for antibody generation as well. Those li-
braries are based on IgM antibodies from 98 human donors 
with HAL9 containing rAbs with VL domains of the lambda 
type and HAL10 containing rAbs with VL domains of the 
kappa type [48]. IgM antibodies represent naive antibody 
variants before affinity maturation and show more diversity 
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compared to the IgG antibody variants. In a previous study, 
the naive libraries HAL7 and HAL8 (the antibody genes of 
HAL7 were included in HAL9 and HAL10 [48]) were used un-
suĐĐessfullǇ for geŶeratioŶ of β-(1,3)-D-glucan binding anti-
bodies. An investigation unraveled that adsorption of 
β-(1,3)-D-glucans to common multiwell plate materials was 
unstable and led to a loss of glucan and therefore β-(1,3)-D-
glucan binding antibodies during panning. The only antibody 
isolated is directed against proteins associated with the glu-
cans [62]. Here, the antibody generation from the naive li-
braries was repeated with proteinase K treated SCH as anti-
gen immobilized in Carbo-BIND® multiwell plates was suc-
cessfully established. The Carbo-BIND® multiwell plates 
from Corning (New York, USA) are functionalized with hydra-
zide-groups which react selectively with the anomeric car-
bon of the reducing end in carbohydrates, forming a cova-
lent bond. This allowed the site-specific and covalent immo-
bilization of chemically unmodified SCH [84]. Besides, two 
more methods based on magnetic beads which are function-
alized with hydroxyl- or hydrazide groups for covalent immo-
bilization were established successfully. But those methods 
were not applied further due to the multiwell plate-based 
protocol of the antibody isolation procedure. 
Discussion 
122 
By panning, screening and sequencing, 4 individual rAbs 
from the immune library and 11 rAbs from the naive library 
HAL9 were isolated. Interestingly, from the immune library 
only rAbs with VL domains of the kappa type were obtained 
and from the naive libraries only with VL domains of the 
lambda type (HAL9). This observation can be concluded back 
to the natural proportion of VL domain types in human and 
mice. The lambda type is predominant in human antibody 
variants (65 %) while it is the opposite in mice (5 %) [27]. 
Therefore, the likeliness to isolate antibodies with lambda 
type VL domains from the naive library and with kappa type 
VL domains from the immune library was foreseeable, even 
with the bias from preferred production of the lambda type 
scFv-Fc by E. coli [48]. 
The characterization of the isolated rAb composed the sec-
ond part of this study. It involved the analysis of binding 
strength and binding specificity. Therefore, the antibodies 
were cloned from the monovalent scFv into the bivalent 
scFv-Fc format with the Fc part of mouse IgG (isotype 2c). 
The format enhances the binding strength of the antibodies 
due to the avidity effect with the second scFv and the Fc part 
allows the direct use of established anti-mouse-Fc antibody 
conjugates for detection in the other experiments.  
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With the titration ELISA on SCH-PK the half maximal effective 
concentration (EC50) of the rAbs was calculated, which al-
lows the comparison of binding strength. This value was 
used for comparison of the antibodies instead of the disso-
ciation constant (KD), representing the binding affinity of the 
antibody paratope for its epitope. The reason lies in the in-
homogeneity of the SCH molecule size and the highly repet-
itive structure that displays a multivalent antigen. Therefore, 
affinity measurements would just result in apparent affini-
ties since the avidity effects cannot be clearly defined. How-
ever, the EC50 values range from 0.16 nM for JoJ48C11 to 
6.61 nM of JoJ58A2, indicating that JoJ48C11 is the antibody 
with the highest binding strength by showing the lowest 
EC50 value.  
Binding specificities of the rAbs were tested via competition 
ELISA with solved competitors and immobilized SCH-PK. The 
advantage of this method was the independency of immobi-
lization efficiency of the single competitors and the possibil-
ity to observe the binding in solution. For comparison, the 
EC50 values of the competitors were calculated. 
In a first experiment with SCH-PK as competitor, only 5 of 
the 15 isolated rAbs showed the expected signal decrease 
with rising concentration of solved SCH-PK. The other rAbs 
were probably directed against the linker-region between 
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SCH and Carbo-BIND plate. From the 5 positive tested rAbs, 
the rAb JoJ48D6 was omitted due to its scarcely production 
and low binding strength. The 4 residual rAbs JoJ48C11, 
JoJ48F1, JoJ49D10 and JoJ58B9 were used for a more de-
tailed investigation. Interestingly, next to the same origin, 
JoJ48C11, JoJ48F1 and JoJ49D10 share a high identity. 
The second more detailed competition ELISA showed that all 
of the tested rAbs binds to different SCH preparations (SCH-
PK, non-treated SCH, SCH from Contipro Biotech) and prep-
arations of other β-(1,6)-ďraŶĐhed β-(1,3)-D-glucans 
(Scleroglucan, Cinerean, Fructigan). The Scleroglucans (non- 
and PK-treated Scleroglucan of S. rolfsii, Scleroglucan of 
S. glucanicum, Actigum™ CS 11) and Cinerean consist of the 
same primary molecular structure as SCH and show a triple 
helical conformation as well [85, 86]. Fructigan is slightly dif-
ferent with the positioŶ of the β-(1,6)-bound D-glucose var-
ying at every second or third glucose moiety of the β-(1,3)-
chain [87, 88]. Its secondary structure is considered to be a 
triplex as well. 
Binding was not observed for the polysaccharides Xanthan 
and Dextran, demonstrating that there are any unspecific in-
teractions of the rAbs with high molecular polysaccharides 
of different glycosidic linkages. Xanthan has a β-(1,4)-D-glu-
can backbone with β-(1,3)-linked β-D-mannose-(1,4)-β-D-
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glucoronic acid-(1,2)-α-D-mannose side chain at every sec-
ond glucose and forms a double helix in aqueous solution 
[89]. Dextran is an α-(1,6)-D-glucan with around 5 % α-(1,3)-
branches to a single glucose or a dimer of glucose [90]. Fur-
thermore, there was not an interaction with D-glucose, Lam-
inarihexaose (linear hexamer of β-(1,3)-bound D-glucose) 
and β-(1,6)-D-gentiobiose (dimer of β-(1,6) bound D-glu-
cose), indicating that D-glucose and the β-(1,6)- or β-(1,3)-
linkage of D-glucose are not alone sufficient for recognition. 
Yeast extract and glucanase-treated SCH does not show 
binding as well, assuring that there was not an interaction of 
the rAbs with impurities from culture media or degraded 
saccharides and other SCH associated components. These 
results suggest that the rAbs interact with the high molecu-
lar structure of the β-(1,6)-branched β-(1,3)-D-glucans and, 
therefore, they are specific for SCH and glucans with the 
same structural properties. 
Further investigation for identification of the possible anti-
gen epitope structure was intended with NaOH treated SCH-
PK and Laminarin. A slight signal decrease at higher concen-
trations of NaOH treated SCH-PK was observed for each rAb. 
This indicates that the native triple helical structure is an im-
portant factor for the recognition of the β-(1,6)-ďraŶĐhed β-
(1,3)-D-glucan molecule by the selected antibodies, since 
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the primary structure is not changed but the secondary 
structure. The residual interaction could be explained by oc-
casional formation of triple helical stretches inside the pre-
dominant random coils and small amounts of renatured SCH 
triplex [10, 91, 92]. JoJ48F1 showed a slight interaction with 
the oligosaccharide Laminarin. It is produced by the algae 
Laminaria digitata and consists of a β-(1,3)-D-glucan main 
chain with an occasional β-(1,6)-bound D-glucose. While it 
exists predominantly as linear molecule, approximately 5 % 
occur as a triplex [93]. A similar interaction of Laminarin with 
JoJ48C11 cannot be fully excluded, since it was once ob-
served in the mentioned previous experiment (Supple-
mental Figure 11-1).  
Therefore, the results showed that the triple helical struc-
ture of the glucans is the essential factor for antibody recog-
nition, which implies that the antibodies bind to the inter-
chain regioŶ. It is also assuŵed that at least oŶe β-(1,6)-
linked D-glucose residue is part of the antigen epitope, since 
it could not be fully excluded with the experiments. Further-
more, paratope structures of antibodies have a diameter of 
roughly 30 Å [94]. A triple helical SCH stretch of this size pre-
seŶts ϵ β-(1,6)-linked glucose residues protruding to the out-
side in every direction, rather unlikely that none of those res-
idues are involved in the interaction with the antibodies. 
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Fructigan possesses a higher degree of branching points 
Đoŵpared to the other β-(1,6)-ďraŶĐhed β-(1,3)-D-glucans 
but does not increase the reactivity of the antibodies, possi-
bly indicating an optimal branching degree of ca 33 % due to 
steric effects of the antibody. Laminarin shows not only a 
low occurrence of triplex structure but additional a lower de-
gree of branching which could explain the weak antibody 
binding. Eventually, this leads to the additional conclusion 
that ďesides the tripleǆ the β-(1,6)-branching degree also in-
fluences antibody reactivity. 
EC50 values could be determined just for the β-(1,6)-
branched β-(1,3)-D-glucans (except for NaOH treated SCH). 
In dependence of the rAb, the EC50 values differ for each 
glucan preparation. For JoJ48C11, JoJ48F1 and JoJ49D10 a 
similar trend was observed with Scleroglucan from S. glu-
canicum showing the highest interaction. For JoJ58B9 the 
highest interaction was observed with SCH-PK as competitor 
and the diversity of the EC50 values between each glucan 
was smaller (1.5 to 6.9 µg mL-1) compared to the other rAbs 
(0.4 to 88.5 µg mL-1). The difference of EC50 values by 
JoJ48C11, JoJ48F1 and JoJ49D10 between the glucans can be 
explained by different molecular size distribution, additional 
macro molecular structures depending on the production 
strains and downstream processing. For example, SCH and 
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SCH-PK showed similar EC50 values because both derived 
from the same batch production and were identically puri-
fied except proteinase K treatment. The commercial SCH 
purchased by Contipro Biotech, produced and purified in un-
known procedures, showed lower EC50 data. JoJ58B9 seems 
to be less sensitive to the macro molecular differences indi-
cating different molecular interactions. 
However, with the investigation of the binding specificity 
false positive anti-SCH rAbs and a more general specificity 
for β-(1,6)-ďraŶĐhed β-(1,3)-D-glucan of the positive anti-
SCH rAbs were identified. Also, a hypothesis about the anti-
gen recognition could be concluded, which proposes a con-
formational epitope requiring an intact triple helical second-
ary structure of β-(1,6)-ďraŶĐhed β-(1,3)-D-glucans with an 
optiŵal ďraŶĐhiŶg degree of oŶe β-(1,6)-bound D-glucose at-
tached to approximately every three glucose units of the 
main chain. 
The third part of this study was performed in cooperation 
with Prof. Dr. Wulf Blankenfeldt and Dr. Kwang Hoon Sung 
froŵ the ǁorkiŶg group ͞StruĐture aŶd FuŶĐtioŶs of Pro‐
teiŶs͟ ;Helŵholtz-Centre for Infection Research in Braun-
schweig). In this part, the main subject of interest was the 
validation of the stated hypothesis about the binding 
epitope of SCH for the isolated antibodies. The strategy was 
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the structure analysis of the antibody paratope via X-ray 
crystallography from which the antigen epitope could be 
concluded. 
For the structure analysis, the rAb JoJ48C11 was produced 
as chimeric Fab fragment with human constant domains (CL-
kappa and CH1). The Fab format is a commonly used anti-
body format for crystallographic experiments. It still consists 
the antigen binding ability but misses the hinge region in the 
scFv-Fc format which could hinder the formation of suitable 
crystals [95]. JoJ48C11 was the only rAb used from the im-
mune library for these experiments since it shares high iden-
tity with JoJ48F1 and JoJ49D10. JoJ58B9 from the naive li-
brary was considered for the structure analysis as well but 
was not further pursued due to missing productivity as Fab. 
The structure of JoJ48C11 Fab was successfully solved and 
refined to a resolution of 3 Å (PDB entry 6EV1). In silico dock-
ing studies with the repeating unit of SCH on this apo struc-
ture identified a possible cavity-shaped binding site for a β-
(1,3)-bound D-glucose residue of SCH. Furthermore, a suc-
cessful co-crystallization with Laminarihexaose (hexamer of 
β-(1,3)-bound D-glucose) was possible by soaking of the pro-
tein crystal with the respective solution. The complex struc-
ture was solved and refined with 2.4 Å resolution (PDB entry 
6EV2). In that complex structure, the electron densities of 
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two glucose residues from Laminarihexaose were observed. 
One of those glucose residues was located in another cavity 
structure of the paratope and therefore identified a second 
binding site. The gathered information from the crystallog-
raphy and in silico docking studies revealed a paratope struc-
ture with two distinct cavity shaped binding sites which are 
approximately 18 Å apart and connected by a shallow 
groove. 
For the paratope structure of anti-carbohydrate antibodies, 
principle characteristics were early defined by studies of 
anti-Dextran binding antibodies. They propose, that respec-
tive antibodies consist of a cavity shaped paratope for ac-
commodation of terminal saccharide residues or a groove 
structure for up to seven internal saccharide residues of a 
linear polysaccharide chain [96, 97]. Up to today, the struc-
tures of only a few anti-carbohydrate antibodies have been 
solved by X-ray crystallography. They show the predicted 
cavity or groove structures of their paratope and some even 
consist of a combined structure of both types [98]. To name 
one example that is particular interesting for this study, the 
monoclonal antibody F22-4, which is directed against the O-
antigen (lipopolysaccharide) from serotype 2a Shigella 
flexneri, consist of a groove shaped paratope with two small 
cavities integrated. Somewhat resembling the suggested 
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JoJ48C11 paratope structure. Co-crystallization of F22-4 
with a synthetic fragment (decasaccharide) of the O-antigen 
clearly showed the binding-orientation of the helical bowed 
fragment along the groove with two branches of single glu-
cose residues fitting into the small cavities [99]. 
Like for F22-4, the generation of a complex structure with 
the full antigen epitope was tried by using native SCH. De-
spite extensive attempts, it was not possible to generate a 
co-crystal with SCH. But parallel experiments with the avail-
able saccharide Laminarihexaose resulted in the JoJ48C11 
Fab/Laminarihexaose complex structure as mentioned. In-
terestingly, JoJ48C11 does not show no binding to Laminari-
hexaose in the competitive ELISA assay. Assumably, the re-
stricted movement inside the crystal led to a stable arrange-
ment of the molecule on the paratope, caused by interac-
tions partly involved in binding of SCH. This in mind, the par-
allel experiments with the carbohydrates representing SCH 
primary structure features was conducted. Davies et al. used 
a similar approach to generate an antagonist for an receptor 
based on the information from co-crystals with low affinity 
fragments [100]. 
However, without a complex structure from crystallography 
studies with SCH, the JoJ48C11 Fab/SCH complex structure 
was modeled in silico. Therefore, the structure of triple 
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helical SCH was modeled from experimental literature data 
and posed onto the paratope structure of the JoJ48C11. Po-
sitioning was carried out by fitting protruding β-(1,6)-bound 
D-glucose moieties into the cavity shaped binding site, as ob-
served for the antibody F22-4 [99]. This arrangement was 
supported by the distance of the two binding sites of 18 Å 
which corresponds strikingly well with the helical pitch dis-
tance of the SCH chains in the triple helical conformation. 
Although the generated model was quite reasonable, fur-
ther experimental validation was achieved by antigen ELISA 
experiments with alanine mutants of JoJ48C11. The model 
suggested 15 amino acid residues of JoJ48C11 to be involved 
in SCH binding which were replaced by alanine to confirm 
their importance. The residues Tyr27H, His35H, Trp47H, 
Trp100H, Asp105H, Asp49L, Lys52L and Trp90L could be vali-
dated. 
In the following their involvement in binding is discussed: 
Asp105H was identified to be a critical residue of JoJ48C11 
due to complete abrogation of binding by its mutation. The 
acidic residue is a part of the binding cavity detected in the 
resolved complex structure of JoJ48C11 Fab with Laminari-
hexaose. There, it was shown to engage in bidentate hydro-
gen bonds with the glucose of the non-reducing end of Lam-
inarihexaose. The complex model with SCH suggests a 
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similar interaction for binding one of the β-(1-6)-linked moi-
ety from SCH chain 1. Those interactions are an important 
motif in protein/carbohydrate complexes [101]. 
His35H, Trp47H, Trp100H and Trp90L are part of the second 
binding cavity which was identified by in silico docking with 
the SCH RU. They act as walls of the cavity and based on their 
nature are suggested to bind the second β-(1-6)-linked moi-
ety from SCH chain 1 through aromatic interactions [101]. 
These types of residues are often found in carbohydrate 
binding sites and their interactions with saccharides are 
known to determine the specificity of carbohydrate binding 
proteins. In contrast to this, their contribution to the stability 
of such complexes is rather modest, which is in line with the 
observation that mutation of these residues lead to a smaller 
affinity decrease than in the case of Asp105H [102, 103]. The 
function of Trp47H and Trp100H probably even extends be-
yond establishing aromatic contacts. Trp47H seems to be an 
important structural element, as conserved residue in frame 
work 2 of the VH domain. Herold et al. reported that substi-
tution of Trp47H in the antibodies MAK33 (mouse IgG, anti-
creatine kinase-M) and 2A2 rheumatoid factor (human IgM, 
anti-human IgG Fc, named 1HEZ in reference) results in the 
destabilization of the VH domain structure as well as the 
VH/VL association [104]. Trp100H is assumed to form a 
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hydrogen bond between the indole group and a β-(1,3)-glu-
cose moiety of SCH chain 2, according to the generated 
model. Similar interaction was observed by Cygler et al. for 
an antibody against polysaccharide O-antigen of pathogenic 
Salmonella of serogroup B [105]. 
Tyr27H, Asp49L and Lys52L were only discovered through the 
JoJ48C11/triple-helical SCH complex model to be potentially 
involved in SCH recognition. Tyr27L is proposed to interact 
with a β-(1,6)-bound glucose of SCH chain 3, while Asp49L 
and Lys52L eŶgage iŶ hǇdrogeŶ ďoŶds ǁith oŶe β-(1,3)-
bound glucose unit of the same SCH chain. Especially Asp49L 
seems to be important since mutation to alanine largely de-
creases the binding affinity of JoJ48C11. 
The identification of residues involved in SCH recognition 
along the paratope validate the in silico generated JoJ48C11 
Fab/SCH complex structure. Additionally, the results of the 
mutant binding studies allow an assumption of binding 
mechanism. Binding of SCH is probably induced by the 
strong interaction with Asp105H of the first binding cavity 
and Asp49L due to hydrogen bonds, while the residues of the 
second binding site contribute to the specificity of the anti-
body by further stabilization of the binding complex, as men-
tioned before.  
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Of course, the roles of the individual residues may just be 
suggestions, since the mutations could have led to unfavor-
able alterations of the paratope structure which were not 
further investigated. But anyway, the modeled complex is 
validated due to confirmation of the involvement of the two 
binding cavities for β-(1,6)-linked glucose residues. The first 
cavity with Asp105H was approved directly by structural 
analysis with complex structure of Laminarihexaose and ala-
nine mutation. The second binding site detected by in silico 
studies showed clearly space for one glucose residue and al-
anine mutations led to reduced binding strength, because of 
either structural changes in this binding site hindering the 
incorporation of the β-(1,6)-linked glucose residue or miss-
ing interacting amino acid residues. 
 
Overall, in this study the 3 highly similar rAbs JoJ48C11, 
JoJ48F1 and JoJ49D10 from an immune antibody library and 
the rAb JoJ58B9 from a naive antibody library were isolated. 
Reports about generation of other antibodies against SCH do 
exist. In 1990, a polyclonal antiserum from immunized rab-
bits was described by Tabata et al. [106]. Later on, Hirata et 
al. reported the isolation of a monoclonal antibody which 
was identified by binding to BSA coupled SCH [107]. In con-
trary to this study, they describe the generation of a 
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polyclonal antiserum from rabbits and a monoclonal anti-
body via hybridoma technology. Thus, here, the first gener-
ation of recombinant anti-SCH antibodies by phage display 
technology from immune- and naive antibody libraries is de-
scribed. 
Via ELISA-based binding studies with different carbohy-
drates and modified SCH preparations, the rAbs were iden-
tified to recognize SCH and other high molecular β-(1,6)-
branched β-(1,3)-D-glucans by their triple helical structure 
ǁith the protrudiŶg β-(1,6)-linked glucose residues. Other 
studies about hybridoma antibodies generated for β-(1,3)-D-
glucans report a similar binding specificity to more than one 
glucan as well [108–113]. Worth mentioning is the isolation 
of two antibodies against the eǆtraĐellular β-glucan of Pleu-
rotus ostreatus by Semedo et al.. The molecular structure of 
this glucan is similar to SCH. It is assumed that these anti-
bodies recognize and bind to a common conformational 
epitope, like the rAbs of this study. In difference to their in-
vestigations, here, it was proven that the triple helical ar-
rangement is an essential element for the recognition by 
binding studies with proteinase and endoglucanase treated 
SCH as well as with denatured SCH. 
For the rAb JoJ48C11, its structure was solved by X-ray crys-
tallography. Even further insight into SCH binding was 
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obtained, by modeling of a JoJ48C11 Fab/SCH complex 
based on the results from structure analysis of a JoJ48C11 
Fab/Laminarihexaose complex and in silico docking of SCH 
RU onto the JoJ48C11 Fab structure. The generated model is 
consistent with experimental data and supports our hypoth-
esis that the β-(1,6)-bound D-glucose residues in conjunction 
with the triple-helical structure constitute the binding 
epitope for the antibody JoJ48C11. Therefore, this study pro-
vides first insight into the structural principles that govern 
the binding of triple-helical SCH to a SCH-specific antibody 
and represents an additional example of an anti-carbohy-
drate antibody structure in complex with its antigen.
5 Prospective 
This study describes the successful generation of monoclo-
nal recombinant antibodies from mouse and human sources 
against the β-D-glucan Schizophyllan via phage display. The 
investigations showed that the antibodies recognize the 
macromolecular structure of the triple helical conformation 
with protruding glucose residues. For the antibody JoJ48C11 
this was directly confirmed by modeling of a Fab/SCH com-
plex based on X-ray crystallography analysis and computa-
tional docking simulation. 
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Due to the high versatility of applications for SCH the gener-
ated antibodies can be used as tool for analytical investiga-
tions of respective preparations. They are suited for the de-
termination of content of SCH or of other glucans with the 
same macromolecular structure in respective preparations. 
The conformational specificity of the antibodies may also be 
used for the quality control of SCH preparation by determi-
nation of changes in their conformation. Furthermore, the 
rAbs could support studies investigating the biological activ-
ity of SCH in mammals and also in studies for understanding 
the biosynthesis of SCH which are both not completely un-
derstood until now. 
But there is room for further investigations of the rAbs as 
well. For example, the successful structure generation of 
JoJ58B9 would be informative. Despite of JoJ48F1 and 
JoJ49D10 which share a high identity with JoJ48C11 and 
therefore are likely to have nearly the same structure, 
JoJ58B9 consist of a different primary sequence especially in 
the CDRs. The insight into the structure of JoJ58B9 may offer 
an alternative binding complex and give another example of 
SCH recognition. Another point could be an investigation, if 
the biological activity of SCH can be further improved by the 
rAbs themselves or by rAb conjugates with other biological 
active compounds using SCH as carrier. Further 
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development to higher binding strength or higher specificity 
for one glucan may be also possible by additional in vitro 
maturation of the antibodies. It may also be possible to use 
in vitro maturation for the development of catalytical active 
antibodies which allow the directed modification or hydrol-
ysis of SCH based on the generated rAbs. 
6 Summary 
Schizophyllan is a β-(1,6)-ďraŶĐhed β-(1,3)-D-glucan that can 
be used for a variety of applications due to its physical prop-
erties and bioactivity. It is produced by the basidiomycete 
Schizophyllum commune as an extracellular homopolysac-
charide. Aqueous solutions consist of a pseudo plastic flow 
behavior, due to its rod-like macromolecular structure which 
is stable at temperatures up to 135 °C and at pH values up to 
pH 12. This makes it interesting for the food, cosmetic and 
oil industry. The bioactivities, like antitumoral and immuno-
modulating effects which are interesting for the pharmaceu-
tical industry are based on enhancement of cell-mediated 
immune response. Due to these various applications of SCH 
the generation of antibodies would be of great value be-
cause they could be used as tool for quantitative analysis 
and for the investigation of glucan bioactivity. 
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In this study the successful generation of four recombinant 
monoclonal antibodies (rAb) which bind to SCH is described. 
The rAbs JoJ48C11, JoJ48F1 and JoJ49D10 were generated 
from a constructed immune library and JoJ58B9 from the na-
ive library HAL9 via phage display technology. Immuno-
chemical ELISA experiments for characterization of the rAbs 
specificity showed that the antibodies are not directed solely 
against SCH but also agaiŶst other β-glucans consistent of a 
β-(1,3)-D-glucan backbone with protruding β-(1,6)-linked 
glucose residues at every third β-(1,3)-D-glucose moiety 
forming a triplex structure, like Scleroglucan, Cinerean and 
Fructigan. Additionally, the molecular structure of JoJ48C11 
as Fab and a complex structure with Laminarihexaose were 
solved using X-ray crystallography. From the gained struc-
tural data and computational docking models a respective 
binding complex was modeled and validated by mutagenesis 
studies. With this the assuŵed ĐoŵďiŶatioŶ of the β-(1,6)-
bound glucose residues and the triple helical structure as 
conformational antigen epitope could be proved for 
JoJ48C11. 
Taken together this study describes the first successful gen-
eration of monoclonal antibodies via phage display from a 
human naive and mouse immune antibody library, which 
reĐogŶize a struĐtural epitope of β-(1,6)-ďraŶĐhed β-(1,3)-D-
Summary 
141 
glucans like SCH. Additionally, it shows the first structural de-
scription of such an anti-β-D-glucan antibody complex which 
was further validated by mutagenesis studies. 
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11 Supplemental Information 
Table 11-1 Data collection and refinement statistics of struc-
tures from X-ray crystallography 
 JoJ48C11 Fab JoJ48C11 Fab + Laminarihexaose 
Data collection   
  X-ray sourcesa P11, DESY P11, DESY 
  Space group P21 P21 
  Cell dimensions   
    a, b, c (Å) 94.08 112.83 140.82 81.73 131.50 91.03 
    α, β, γ ;°Ϳ 90.00, 98.61, 90.00 90.00, 91.50, 90.00 
  No. of subunits/ASUb 6 4 
  Wavelength (Å) 1.03320 1.03320 
  Resolution (Å) 3.04 (3.096-3.043)c 2.40 (2.445-2.403)c 
  Total number of observation 188636 (9678) 516202 (26154) 
  Total number unique  55718 (2768) 74793 (3694) 
  Rsym (%)d 13.0 (64.7) 9.6 (77.9) 
  Rmeas or Rr.i.m. (%)e 15.5 (76.4) 10.3 (84.0) 
  Rpim (%)f 8.3 (40.4) 3.9 (31.2) 
  Mean(I)/sd(I) 8.9 (2.2) 12.9 (2.2) 
  Completeness (%) 99.4 (99.3) 100.0 (99.6) 
  Multiplicity    3.4 (3.5) 6.9 (7.1) 
Refinement   
  Resolution range (Å) 56.416-3.043 55.787-2.403 
  Reflections used  55674 74686 
  Rwork / Rfree (%)g 18.56 / 23.79 19.35 / 23.29 
  Number of atoms   
    Protein 19269 13102 
    Ligand  35 
    Water 9 
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Average B factors (Å2)   
Protein 66.58 57.18 
Ligand  97.28 
Water 35.30 49.31 
  RMS deviations   
    Bond length (Å) 0.004 0.004 
    Bond angles (°) 1.003 0.756 
  Ramachandran outliers (%) 0.08 0.23 
  PDB ID 6EV1 6EV2 
aDESY : German Electron Synchrotron, Germany 
bASU; Asymmetric Unit 
cValues in parentheses are for reflections in the highest resolution bin. 
dRsym = ΣhΣi|I(h,i) <I(h)>|/ΣhΣi I(h,i), where I(h,i) is the intensity of the ith measurement of reflec-
tion h and <I(h)> is the corresponding average value for all i measurements. 
eRmeas = Rr.i.m. (redundancy-independent merging R-factor) = 
Σh[N/;N−ϭͿ]1/2Σi(|Ii(h)−<I(h)>|Ϳ/ΣhΣiIi(h) 
fRp.i.m. (precision-indicating merging R-faĐtorͿ = Σh[ϭ/;N−ϭͿ]1/2Σi(|Ii(h)−<I(h)>|Ϳ/ΣhΣiIi(h) 
gRwork = Σ||Fo|–|Fc||/Σ|Fo|, where Rfree is calculated for the 5% test set of reflections. 
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Figure 11-1 Competitive ELISA of rAb JoJ48C11 with different 
competitors. This example shows the half logarithmic plotted 
absorbance signals from the competitive ELISA with JoJ48C11 
(as scFv-Fc). Serial dilutions ranging from 0.32 µg mL-1 to 
316 µg mL-1 of the competitors were incubated with each rAb 
in the scFv-Fc format before application on SCH-PK loaded 
Carbo-BIND™ ŵultiǁell plates. The rAďs ǁere also iŶĐuďated 
without competitor as negative control and mark of maximal 
signal. 
 
 
